September 2000

Dear Reader:

The Food and Drug Administration (FDA) is pleased to provide you the newly revised

breast implant consumer handbook entitled, “Breast Implants – An Information Update –

2000.”

This handbook contains the latest information about breast implants to assist you in

making an informed decision about whether or not to have breast implants.

It includes topics such as availability of breast implants, potential risks, answers to the

most frequently asked questions by consumers, reporting of serious problems, chronology

of FDA activities related to breast implants, and breast implant resource groups.

We hope the information in this breast implant handbook will be helpful to you. You

may duplicate it for further distribution without permission.

The Consumer Affairs Staff of FDA’s Office of Health and Industry Programs (OHIP) is

responsible for answering breast implant calls and distributing the breast implant

handbook. For specific information on how to obtain a copy of this handbook or to talk

to a Consumer Affairs Specialist, refer to the Breast Implant Resource Groups section.

This breast implant consumer handbook, along with other breast implant information,

may also be obtained by visiting FDA’s website at

http://www.fda.gov/cdrh/breastimplants/.

If you have any comments regarding the breast implant handbook, please write to us at

FDA, Office of Device Evaluation, Division of General, Restorative, and Neurological

Devices, 9200 Corporate Boulevard, HFZ-410, Rockville, MD 20850.

Sincerely yours,

David W. Feigal, Jr. M.D., M.P.H.

Director

Center for Devices and Radiological Health
i

CONTENTS

INTRODUCTION ............................................................................................1

STATUS / AVAILABILITY OF IMPLANTS ..................................................3

Status of silicone gel-filled breast implants...........................................................................3

Status of saline-filled breast implants.....................................................................................4

Status of alternative breast implants.......................................................................................5

THE SURGERY...............................................................................................6

General description of breast surgery .....................................................................................6

Your expectations - reconstruction or augmentation............................................................6

Postoperative care......................................................................................................................7

Special surgical concerns for women with breast cancer.....................................................8

Choices in reconstructive procedures.....................................................................................9

Breast reconstruction with breast implants............................................................................9

Timing of breast implant reconstruction ..............................................................................10

Surgical considerations to discuss.........................................................................................11

Breast implant reconstruction procedures............................................................................11

Breast reconstruction without implants: tissue flap procedure..........................................14

BREAST IMPLANT RISKS ..........................................................................17

OTHER ILLNESSES .....................................................................................29

Connective tissue diseases and related disorders................................................................29

Cancer.......................................................................................................................................34

Breast feeding ..........................................................................................................................35

Effects on children...................................................................................................................36

Other..........................................................................................................................................36

SPECIFIC ISSUES TO CONSIDER..............................................................37

Other factors to consider (choosing a surgeon, implant size and shape, surface

texturing, palpability, implant placement, and incision sites)...........................................37

Questions to ask your surgeon about breast augmentation................................................42

Questions to ask your surgeon about breast reconstruction...............................................43
ii

FREQUENTLY ASKED QUESTIONS..........................................................44

What information should I get for my records?...................................................................44

Should I tell other doctors in the future about my implants?.............................................46

Do I need to get regular mammograms?...............................................................................46

What about the Trilucent (soybean oil-filled) implants? ................................................47

Is there a test to detect silicone in the body or to determine whether an individual is

sensitive to silicone? ...............................................................................................................48

REPORTING OF SERIOUS PROBLEMS / MEDWATCH..........................50

CHRONOLOGY OF FDA BREAST IMPLANT ACTIVITIES....................56

BREAST IMPLANT RESOURCE GROUPS ................................................65

Manufacturers..........................................................................................................................65

Physician, Nursing, and Industry Groups.............................................................................66

Consumer Groups....................................................................................................................69

Federal Government................................................................................................................72

CURRENT BIBLIOGRAPHIES....................................................................74

FDA FREEDOM OF INFORMATION .........................................................75
1

INTRODUCTION

FDA was given the responsibility for regulating medical devices, such as breast implants,

under a law called the Medical Device Amendments of 1976. The law requires

manufacturers of new medical devices to show that the devices are safe, effective, and

properly labeled before they are allowed on the market. Devices in use before the 1976

law, including saline-filled and silicone gel-filled breast implants, were allowed to stay

on the market. However, the law directed FDA to eventually require scientific evidence

of the safety and effectiveness of many of these pre-1976 devices.

There are three types of breast implants, all of which are intended for breast

augmentation, breast reconstruction, and/or revision (i.e., replacement) of a breast

implant. The saline-filled implant has an external silicone shell and is filled with sterile

saline (salt water). The silicone gel-filled implant also has an external silicone shell but

is filled with silicone gel. An alternative breast implant may have a different shell

material and/or a different filler.

While many women believe breast implants cause debilitating systemic illnesses, such as

autoimmune disease, this is not proven at this time. However, most women with breast

implants will experience some local complications such as rupture, pain, capsular

contracture (a tightening of the scar tissue or capsule the body forms around the breast

implant), disfigurement, and serious infection. These may lead to nonsurgical medical

treatments and repeat surgeries.

Well before the date of surgery, you should take the time to carefully read and consider

the information provided in the patient labeling and the device package insert. You

should discuss any questions you have with your doctor before you make your decision.
2

Additionally, the following are important factors for you to consider when deciding to

have implants:

1. Whether you are undergoing augmentation or reconstruction, be aware that breast

implants are not considered lifetime devices and that breast implantation may not be a

one-time surgery. You are likely to need additional surgery(ies) and doctor visits over

the course of your life. You are also likely to have surgery to remove the implant

with or without replacement sometime over the course of your life.

2. Many of the changes to your breast following implantation are irreversible (cannot be

undone). If you later choose to have your implant(s) removed, you may experience

unacceptable dimpling, puckering, wrinkling, loss of breast tissue, or other cosmetic

changes of the breast.

3. Breast implants may affect your ability to breast feed. Also, breast implants will not

prevent your breast from sagging after pregnancy.

4. With breast implants, routine screening mammography will be more difficult, and you

will need to have additional views, which means more time and radiation.

5. Breast implant surgery and/or treatment of complications may not be covered by your

health insurance. You should check with your insurance company regarding these

coverage issues because, for some women, health insurance premiums may increase,

coverage may be dropped, and/or future coverage may be denied.
3

STATUS / AVAILABILITY OF IMPLANTS

Status of Silicone Gel-Filled Breast Implants

On April 10, 1991, FDA asked the manufacturers to submit evidence in a premarket

approval (PMA) application that silicone gel-filled breast implants were safe and

effective. However, they were unable to provide FDA with this information. Without

enough data on safety and effectiveness, FDA determined that silicone gel-filled breast

implants could not be approved. Therefore, silicone gel-filled breast implants were

removed from the open market. However, silicone gel-filled implants are available to

women through the following FDA-approved studies:

• an adjunct study

• an investigational device exemptions (IDE) study

An adjunct study is a study developed for continued availability of silicone-gel breast

implants for a public health need. In April 1992, after a careful evaluation of the public

health need, the alternatives to silicone gel-filled breast implants, and the risks, FDA

concluded that silicone gel-filled breast implants should continue to be available for

women seeking breast reconstruction or revision of an existing breast implant.

Accordingly, the adjunct study was developed to make silicone gel-filled breast implants

available for reconstruction and revision patients and to collect short-term complication

data. Eligible women include those who have had breast cancer surgery, a severe injury

to the breast, a birth defect that affects the breast, or a medical condition causing a severe

breast abnormality. Additionally, those who need to have an existing implant replaced

for medical reasons, such as rupture of the implant, are also eligible. Women who want

silicone gel-filled implants for breast augmentation (cosmetic reasons) cannot be enrolled

in the adjunct studies. According to the adjunct study protocols, each woman will be

followed for at least five years.
4

An IDE study is a clinical study that must be reviewed and approved by FDA to help

assure that the resulting data will be meaningful and that patients will not be exposed to

unreasonable risks. Under the law, FDA cannot acknowledge the existence of any study

conducted under the IDE unless the manufacturer publicly announces the existence of the

study. Likewise, FDA cannot release the results of studies conducted under an IDE

unless the manufacturer has made the data publicly available. Generally, these IDE study

data are used as the basis for a future application to market the device. Women

participating in an IDE study would receive their implants for the uses described in the

study protocol/plan. Each woman who participates in an IDE study must give informed

consent, and an Institutional Review Board (IRB) must oversee the study. An IRB is

composed of scientists, health professionals, and community members who do not have a

bias as to the outcome of the study.

To date, both Mentor Corporation and McGhan Medical have adjunct and IDE studies

approved by FDA. For further information on enrolling into one of these studies, contact

your doctor or the manufacturer (see Breast Implant Resource Groups section for

manufacturer contact information).

Status of Saline-Filled Breast Implants

The manufacturers of saline-filled breast implants were notified by FDA in January 1993

that the agency would require data on their products' safety and effectiveness. While the

manufacturers were conducting the required studies, saline-filled breast implants

remained on the market.

On August 19, 1999, FDA asked the manufacturers to submit evidence in a PMA that

saline-filled breast implants were safe and effective. On March 1-3, 2000, FDA’s

General and Plastic Surgery Devices Panel met to review PMAs for saline-filled breast
5

implants manufactured by Mentor Corporation, McGhan Medical, and Poly Implant

Protheses (PIP). The Panel voted to recommend approval of Mentor Corporation and

McGhan Medical’s saline-filled breast implants and to recommend disapproval of PIP’s

implants. On May 10, 2000, FDA granted approval of Mentor’s and McGhan’s PMAs.

To date, all other manufacturers’ saline-filled breast implants are considered

investigational.

If you want to receive an implant other than Mentor and McGhan’s, you must enroll in an

IDE study. To enroll in an IDE, contact your doctor or the manufacturer (see Breast

Implant Resource Groups section for manufacturer contact information).

Status of Alternative Breast Implants

Currently, there are no alternative breast implants approved for marketing. As an

investigational device, an alternative breast implant can be made available only through

an IDE study.

To date, there is one approved IDE for an alternative breast implant called the

Trilucent; however, there is no new patient enrollment in this IDE. Refer to the

Frequently Asked Questions section for more information.
6

THE SURGERY

General Description of Breast Implant Surgery

Breast implant procedures can be performed on an outpatient (not hospitalized) basis or

at a hospital. Breast implant surgery can be done under local anesthesia (only breast area

numbed) or under general anesthesia (put to sleep). Breast implant surgery can last from

one to several hours depending on whether the implant is inserted behind (submuscular)

or in front of (subglandular) the chest muscle and whether surgery is performed on one or

both breasts. If the surgery is done in a hospital, the length of the hospital stay will vary

according to the type of surgery, the development of any postoperative complications,

and your general health. It may also depend on the type of coverage your insurance

provides. Before surgery, your doctor should discuss with you the extent of surgery, the

estimated time it will take, and the choice of drugs for pain and nausea.

Your Expectations - Reconstruction or Augmentation

Your consideration of breast implants, for reconstruction or for augmentation, should be

based on realistic expectations of the outcome. You may also want to talk with women

who have had this surgery at least a year ago by the same surgeon. Keep in mind,

however, that there is no guarantee that your results will match those of other women.

Your results will depend on many individual factors, such as

• your overall health

• chest structure and body shape

• healing capabilities (which may be hindered by radiation and chemotherapy,

smoking, alcohol, and various medications)

• bleeding tendencies/likelihood
7

• prior breast surgery(ies)

• possibility of infection

• the skill and experience of the surgical team

• the type of surgical procedure

• the type and size of implant

You will be given general or local anesthesia, and in most cases, antibiotics. The surgery

may last from 1-2 hours for augmentation to several hours for reconstruction or revision.

Scarring is a natural outcome of surgery, and your doctor can describe the location, size,

and appearance of the scars you can expect to have. For most women, scars will fade

over time to thin lines, although the darker your skin, the more prominent the scars are

likely to be. You should ask your doctor about the types of surgical procedures, where

your scar will be, and what to expect after surgery.

Postoperative Care

Your doctor should describe the usual postoperative (after surgery) recovery process, the

possible complications that can arise, and the expected recovery period. Following the

operation, as with any surgery, some pain, swelling, bruising, and tenderness can be

expected. These complications may last for a month or longer, but they should disappear

with time.

Medications for pain and nausea can be prescribed. Some women may experience

bleeding and some may experience fever, warmth, or redness of the breast, or other

symptoms of infection. These symptoms should be reported immediately to your doctor.

You should be told about wound healing and how to care for your wound. Drains may be

used for a few days.
8

Post-operative care may involve the use of a post-operative bra, compression bandage, or

jog bra for extra support and positioning while you heal. At your doctor’s

recommendation, you will most likely be able to return to work within a few days,

although you should avoid any strenuous activities that could raise your pulse and blood

pressure for at least a couple of weeks. Your doctor may also recommend breast massage

exercises.

Ask your doctor about a schedule of follow-up examinations, limits on your activities,

precautions you should take, and when you can return to your normal routine. (If you are

enrolled in a clinical study, your doctor should give you a schedule for follow-up

examinations set by the study plan.)

Special Surgical Concerns for Women with Breast Cancer

The following issues should be considered for women with breast cancer:

• The physical and cosmetic results with breast implants may be affected by

chemotherapy, radiation therapy, or any other factor that significantly alters the

healing process.

• Skin necrosis (cell death) may occur because circulation to the remaining tissue

has been changed by a mastectomy (breast removal). Also, skin necrosis may be

increased as a result of radiation treatment.

• It usually takes more than one operation to achieve the desired cosmetic outcome,

especially if this procedure includes building a new nipple.
9

Choices in Reconstructive Procedures

The type of breast reconstruction procedure available to you depends on your medical

situation, breast shape and size, general health, lifestyle, and goals. Women with small or

medium sized breasts are the best candidates for breast reconstruction.

Breast reconstruction can be accomplished by the use of a breast implant, your own

tissues (a tissue flap), or a combination of the two. A tissue flap is a section of skin, fat

and/or muscle which is moved from your stomach, back or other area of your body, to the

chest area and shaped into a new breast.

Whether or not you have reconstruction with or without breast implants, you will

probably undergo additional surgeries to improve symmetry and appearance. For

example, after your breast has healed from the original implant surgery, you may want to

build a new nipple and darken the areola (skin around the nipple). This procedure can

usually be performed on an outpatient basis. Ask your doctor to explain the various ways

this can be done, such as using a skin graft from the opposite breast or by tattooing the

area.

Ask your doctor about the pros and cons of each implant technique. If you decide to have

reconstruction for one breast, you may need to think about surgery on the other breast to

achieve a similar appearance.

Breast Reconstruction with Breast Implants

Your surgeon will decide whether your health and medical condition makes you an

appropriate candidate for breast implant reconstruction. Women with larger breasts may

require reconstruction with a combination of a tissue flap and an implant. Your surgeon
10

may recommend breast implantation of the opposite, uninvolved breast in order to make

them more alike (maximize symmetry) or he/she may suggest breast reduction (reduction

mammoplasty) or a breast lift (mastopexy) to improve symmetry. Mastopexy involves

removing a strip of skin from under the breast or around the nipple and using it to lift and

tighten the skin over the breast. Reduction mammoplasty involves removal of breast

tissue and skin. If it is important to you not to alter the unaffected breast, you should

discuss this with your surgeon, as it may affect the breast reconstruction methods

considered for your case.

Timing of Breast Implant Reconstruction

The following description applies to reconstruction following mastectomy, but similar

considerations apply to reconstruction following breast trauma or for reconstruction for

congenital defects. The breast reconstruction process may begin at the time of your

mastectomy (immediate reconstruction) or weeks to years afterwards (delayed

reconstruction). Immediate reconstruction may involve placement of a breast implant,

but typically involves placement of a tissue expander, which will eventually be replaced

with a breast implant. It is important to know that any type of surgical breast

reconstruction may take several steps to complete.

Two potential advantages to immediate reconstruction are that your breast reconstruction

starts at the time of your mastectomy and that there may be cost savings in combining the

mastectomy procedure with the first stage of the reconstruction. However, there may be

a higher risk of complications such as deflation with immediate reconstruction, and your

initial operative time and recuperative time may be longer.

A potential advantage to delayed reconstruction is that you can delay your reconstruction

decision and surgery until other treatments, such as radiation therapy and chemotherapy,
11

are completed. Delayed reconstruction may be advisable if your surgeon anticipates

healing problems with your mastectomy, or if you just need more time to consider your

options.

There are medical, financial, and emotional considerations to choosing immediate versus

delayed reconstruction. You should discuss with your surgeon, plastic surgeon, and

oncologist, the pros and cons with the options available in your individual case.

Surgical Considerations to Discuss

Discuss the advantages and disadvantages of the following options with your surgeon and

your oncologist:

• Immediate Reconstruction:

- One-stage immediate reconstruction with a breast implant (implant only).

- Two-stage immediate reconstruction with a tissue expander followed by delayed

reconstruction several months later with a breast implant.

• Delayed Reconstruction:

- Two-stage delayed reconstruction with a tissue expander followed several months

later by replacement with a breast implant.

Breast Implant Reconstruction Procedures

• One-Stage Immediate Breast Implant Reconstruction

Immediate one-stage breast reconstruction may be done at the time of your

mastectomy. After the general surgeon removes your breast tissue, the plastic
12

surgeon will then implant a breast implant that completes the one-stage

reconstruction.

• Two-Stage (Immediate or Delayed) Breast Implant Reconstruction

Breast reconstruction usually occurs as a two-stage procedure, starting with the

placement of a breast tissue expander, which is replaced several months later with a

breast implant. The tissue expander placement may be done immediately, at the time

of your mastectomy, or be delayed until months or years later.

Side View. Breast Side View. Expander

Tissue Removed Inserted and Filled

- Tissue Expansion

During a mastectomy, the general surgeon often removes skin as well as

breast tissue, leaving the chest tissues flat and tight. To create a breast shaped

space for the breast implant, a tissue expander is placed under the remaining

chest tissues.

The tissue expander is a balloon-like device made from elastic silicone rubber.

It is inserted unfilled, and over time, sterile saline fluid is added by inserting a

small needle through the skin to the filling port of the device. As the tissue

expander fills, the tissues over the expander begin to stretch, similar to the
13

gradual expansion of a woman's abdomen during pregnancy. The tissue

expander creates a new breast shaped pocket for a breast implant.

Tissue expander placement usually occurs under general anesthesia in an

operating room. Operative time is generally one to two hours. The procedure

may require a brief hospital stay, or be done on an outpatient basis. Typically,

you can resume normal daily activity after two to three weeks.

Because the chest skin is usually numb from the mastectomy surgery, it is

possible that you may not experience pain from the placement of the tissue

expander. However, you may experience feelings of pressure or discomfort

after each filling of the expander, which subsides as the tissue expands.

Tissue expansion typically lasts four to six months.

- Placing the Breast Implant

After the tissue expander is removed, the breast implant is placed in the

pocket. The surgery to replace the tissue expander with a breast implant

(implant exchange) is usually done under general anesthesia in an operating

room. It may require a brief hospital stay or be done on an outpatient basis.

 

 Post Mastectomy Stage 1: Tissue Expander Stage 2: Breast Implant

and Nipple/Areola Reconstruction
14

Breast Reconstruction Without Implants: Tissue Flap Procedures

The breast can be reconstructed by surgically moving a section of skin, fat, and muscle

from one area of your body to another. The section of tissue may be taken from such

areas as your abdomen, upper back, upper hip, or buttocks.

The tissue flap may be left attached to the blood supply and moved to the breast area

through a tunnel under the skin (a pedicled flap), or it may be removed completely and

reattached to the breast area by microsurgical techniques (a free flap). Operating time is

generally longer with free flaps, because of the microsurgical requirements.

Flap surgery requires a hospital stay of several days and generally a longer recovery time

than implant reconstruction. Flap surgery also creates scars at the site where the flap was

taken and possibly on the reconstructed breast. However, flap surgery has the advantage

of being able to replace tissue in the chest area. This may be useful when the chest

tissues have been damaged and are not suitable for tissue expansion. Another advantage

of flap procedures over implantation is that alteration of the unaffected breast is generally

not needed to improve symmetry.

The most common types of tissue flaps are the TRAM (transverse rectus abdominus

musculocutaneous flap which uses tissue from the abdomen and the Latissimus dorsi flap

which uses tissue from the upper back.

It is important for you to be aware that flap surgery, particularly the TRAM flap, is a

major operation and more extensive than your mastectomy operation. It requires good

general health and strong emotional motivation. If you are very overweight, smoke

cigarettes, have had previous surgery at the flap site, or have any circulatory problems,

you may not be a good candidate for a tissue flap procedure. Also, if you are very thin,
15

you may not have enough tissue in your abdomen or back to create a breast mound with

this method.

• The TRAM Flap (Pedicle or Free)

During a TRAM flap procedure, the surgeon removes a section of tissue from your

abdomen and moves it to your chest to reconstruct the breast. The TRAM flap is

sometimes referred to as a "tummy tuck" reconstruction because it may leave the

stomach area flatter.

A pedicle TRAM flap procedure typically takes three to six hours of surgery under

general anesthesia; a free TRAM flap procedure generally takes longer. The TRAM

procedure may require a blood transfusion. Typically, the hospital stay is two to five

days. You can resume normal daily activity after six to eight weeks. Some women,

however, report that it takes up to one year to resume a normal lifestyle. You may

have temporary or permanent muscle weakness in the abdominal area. If you are

considering pregnancy after your reconstruction, you should discuss this with your

surgeon. You will have a large scar on your abdomen and may also have additional

scars on your reconstructed breast.

 

Post Mastectomy TRAM Flap Final Result with

Nipple/AreolaReconstruction
16

• The Latissimus Dorsi Flap With or Without Breast Implants

During a Latissimus Dorsi flap procedure, the surgeon moves a section of tissue from

your back to your chest to reconstruct the breast. Because the Latissimus Dorsi flap is

usually thinner and smaller than the TRAM flap, this procedure may be more

appropriate for reconstructing a smaller breast.

The Latissimus Dorsi flap procedure typically takes two to four hours of surgery

under general anesthesia. Typically, the hospital stay is two to three days. You can

resume daily activity after two to three weeks. You may have some temporary or

permanent muscle weakness and difficulty with movement in your back and shoulder.

You will have a scar on your back, which can usually be hidden in the bra line. You

may also have additional scars on your reconstructed breast.

 

 Post Mastectomy View Showing Back Scar Latisimus Dorsi Flap
17

BREAST IMPLANT RISKS

The Institute of Medicine (IOM) completed its independent, unbiased review of all past

and ongoing scientific research study of silicone breast implant safety in June 1999.1

Among the major findings from this study were that local complications with silicone

breast implants were the primary safety issue with breast implants, that these have not

been well studied, and that information on these complications is crucial for women

deciding whether or not they want breast implant surgery. The IOM report said:

“First, reoperations and local and perioperative [right after surgery] complications

are frequent enough to be a cause for concern and to justify the conclusion that they

are the primary safety issue with silicone breast implants. Complications may have

risks themselves, such as pain, disfigurement, and serious infection and they may

lead to medical and surgical interventions, such as reoperations, that have risks.

Second, risks accumulate over the lifetime of the implant, but quantitative data on

this point are lacking for modern implants and deficient historically. Third,

information concerning the nature and the relative high frequency of local

complications and reoperations is an essential element of adequate informed

consent for women undergoing breast implantation.”

There are risks or complications associated with any surgical procedure, such as the

effects of anesthesia, infection, swelling, redness, bleeding, and there are complications

specific to breast implants. These complications are described below.

 

1

 Safety of Silicone Breast Implants. Institute of Medicine National Academy Press, Washington, D.C. 2000. {IOM

Report}
18

1. Capsular Contracture

Capsular contracture is when the scar tissue or capsule that normally forms around the

implant tightens and squeezes the implant. It may be more common following

infection, hematoma (collection of blood), and seroma (collection of watery portion of

blood). There are four grades of capsular contracture - Baker Grades I through IV.

The Baker grading is as follows

Grade I the breast is normally soft and looks natural

Grade II the breast is a little firm but looks normal

Grade III the breast is firm and looks abnormal (visible distortion)

Grade IV the breast is hard, painful, and looks abnormal (greater

distortion)

Additional surgery may be needed to correct the capsular contracture. This surgery

ranges from removal of the implant capsule tissue to removal (and possibly

replacement) of the implant itself. Capsular contracture may happen again after this

additional surgery.

In a prospective clinical study of saline-filled breast implants conducted by Mentor,

the cumulative, 3-year, by patient rates of a first occurrence of capsular contracture

Grades III and IV were 9% for the 1264 augmentation patients and 30% for the 416

reconstruction patients. In a prospective clinical study of saline-filled breast implants

conducted by McGhan, the cumulative, 3-year, by patient rates of a first occurrence of

capsular contracture Grades III and IV were 9% for the 901 augmentation patients and

25% for the 237 reconstruction patients.
19

A randomized controlled study comparing silicone gel-filled and saline-filled

implants in women undergoing reconstruction reported a 54% contracture rate of

Baker Grades III and IV in the silicone gel group after 6 months.2

A retrospective study by Gabriel et al. indicated that 131 of 749 (17.5%) women had

at least one surgical procedure over an average of 7.8 years because of capsular

contracture.3 This would not include capsular contracture that may have been severe

but did not result in surgery. This study included women who had implants for

cosmetic and reconstruction purposes, most of whom had silicone gel-filled breast

implants.

2. Deflation/Rupture/Leakage

Breast implants are not lifetime devices and cannot be expected to last forever.

Some implants deflate or rupture in the first few months after being implanted and

some deflate after several years; others are intact 10 or more years after the surgery.

a. Silicone Gel-Filled Breast Implants - When silicone gel-filled implants rupture,

some women may notice decreased breast size, nodules (hard knots), uneven

appearance of the breasts, pain or tenderness, tingling, swelling, numbness,

burning, or changes in sensation. Other women may unknowingly experience a

rupture without any symptoms (i.e., “silent rupture”). Magnetic resonance

imaging (MRI) with equipment specifically designed for imaging the breast may

be used for evaluating patients with suspected rupture or leakage of their

silicone gel-filled implant.

 

2

 Asplund, O. Capsular contracture in silicone gel and saline-filled breast implants after reconstruction. Plast

Reconstru Surg 1984;73:270-5.
20

Silicone gel which escapes the fibrotic capsule surrounding the implant may

migrate away from the breast. The free silicone may cause lumps called

granulomas to form in the breast or other tissues where the silicone has

migrated, such as the chest wall, armpit, arm, or abdomen.

Plastic surgeons usually recommend removal of the implant if it has ruptured,

even if the silicone is still enclosed within the scar tissue capsule, because the

silicone gel may eventually leak into surrounding tissues. If you are considering

the removal of an implant and the implantation of another one, be sure to discuss

the benefits and risks with your doctor.

FDA completed a retrospective study on rupture of silicone gel-filled breast

implants.4 This study was performed in Birmingham, Alabama and included

women who had their first breast implant before 1988. Women with silicone

gel-filled breast implants had a MRI examination of their breasts to determine

the status of their current breast implants. The 344 women who received a MRI

examination had a total of 687 implants. Of the 687 implants in the study, at

least two of the three study radiologists agreed that 378 implants were ruptured

(55%). This means that 69% of the 344 women had at least one ruptured breast

implant. Of the 344 women, 73 (21%) had extracapsular silicone gel in one or

both breasts. Factors that were associated with rupture included increasing age

of the implant, the implant manufacturer, and submuscular rather than

subglandular location of the implant. A summary of the findings of this study is

also available on FDA’s website at

http://www.fda.gov/cdrh/breastimplants/studies/biinterview.pdf and

http://www.fda.gov/cdrh/breastimplants/studies/birupture.pdf.

 

3 Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton LJ. Complications leading to surgery after

breast implantation. New Engl J Med 1997; 336:679-682.

4 Brown SL, Middleton MS, Berg WA, Soo MS, Pennello G. Prevalence of rupture of silicone gel breast implants in

a population of women in Birmingham, Alabama. American Journal of Roentgenology 2000;175:1-8.
21

Robinson et al. studied 300 women who had their implants for 1 to 25 years and

had them removed for a variety of reasons.5 Visible signs of rupture in 51% of

the women studied were found. Severe silicone leakage (silicone outside the

implant without visible tears or holes) was seen in another 20%. Robinson et al.

also noted that the chance of rupture increases as the implant ages.

Other studies indicate that silicone may escape the capsule in 11-23% of rupture

cases.

6,7,8,9

b. Saline-Filled Breast Implants – Saline-filled breast implants deflate when the

saline solution leaks either through an unsealed or damaged valve or through a

break in the implant shell. Implant deflation can occur immediately or

progressively over a period of days and is noticed by loss of size or shape of the

implant. Some implants deflate or rupture in the first few months after being

implanted and some deflate after several years. You should also be aware that

the breast implant may wear out over time and deflate. Additional surgery is

needed to remove deflated implants.

In a prospective clinical study conducted by Mentor, the cumulative, 3-year, by

patient rates of a first occurrence of deflation were 3% for 1264 augmentation

 

5 Robinson OG, Bradley EL, Wilson DS. Analysis of explanted silicone implants: a report of 300 patients. Ann

Plast Surg. 1995; 34:1-7.

6 Vinnik CA. Migratory silicon - clinical aspects. Silicone in Medical Devices - Conference Proceedings. 1991

February 1-2; Baltimore, MD: U.S. Department of Health and Human Services, FDA Publication No. 92-4249

(p.59-67).

7 Duffy MJ, Woods JE. Health risks of failed silicone gel breast implants: a 30-year clinical experience. Plast

Reconstr Surg 1994;94:295-299.

8 Berg WA, Caskey CI, Hamper UM, Kuhlman JE, Anderson ND, Chang BW, Sheth S, Zerhouni EA. Single- and

double-lumen silicone breast implant integrity: Prospective evaluation of MR and US criteria. Radiology

1995;197:45-52.

9 Gorczyca DP, Schneider E, DeBruhl ND, Foo TKF, Ahn CY, Sayre JW, Shaw WW, Bassett LW. Silicone breast

implant rupture: Comparison between three-point Dixon and fast spin-echo MR imaging. AJR 1994;162:305-310.
22

patients and 9% for 416 reconstruction patients. In a prospective clinical study

conducted by McGhan, the cumulative, 3-year, by patient rates of a first

occurrence of deflation were 5% for the 901 augmentation patients and 6% for

the 237 reconstruction patients.

A retrospective study of saline breast implants by Gutowski et al. indicates that

10.1% of women followed for an average of 6 years had at least one implant

deflated.10

For silicone gel and saline-filled implants, some causes of rupture or deflation include

• damage by surgical instruments during surgery

• overfilling or underfilling of the implant with saline solution (specific only to

saline-filled breast implants)

• capsular contracture

• closed capsulotomy (described below)

• stresses such as trauma or intense physical manipulation

• excessive compression during mammographic imaging

• placement through umbilical incision site

• injury to the breast

• normal aging of the implant

• unknown/unexplained reasons

Closed capsulotomy is a technique used to relieve capsular contracture. It involves

manually squeezing the breast to break the hard capsule. This has been implicated

as a possible cause of breast implant rupture. Closed capsulotomy is not

recommended by breast implant manufacturers.
23

3. Additional Surgeries

You should understand there is a high chance that you will need to have additional

surgery at some point to replace or remove your implant(s) due to problems such as

deflation, capsular contracture, infection, shifting, and calcium deposits. Many

women decide to have the implants replaced, but some women do not. Those who do

not have their implants replaced may have cosmetically undesirable dimpling and/or

puckering of the breast following removal of the implant.

In a prospective clinical study of saline-filled breast implants conducted by Mentor,

the cumulative, 3-year, by patient rates of a first occurrence of additional surgeries

were 13% for the 1264 augmentation patients and 40% for the 416 reconstruction

patients. In a prospective clinical study of saline-filled breast implants conducted by

McGhan, the cumulative, 3-year, by patient rates of a first occurrence of additional

surgeries were 21% for the 901 augmentation patients and 39% for the 237

reconstruction patients.

A retrospective study by Gabriel et al. shows that 24% of women with breast implants

experience adverse events resulting in surgery during the first five years after

implantation (silicone and saline implants were studied together).11 According to this

study, about 1 in 3 women getting breast implants for reconstruction may need a

second surgery within five years, and about 1 in 8 women getting breast implants for

augmentation may need a second surgery within five years. These additional

surgeries may result in the loss of breast tissue.

 

10 Gutowski KA, Mesna GT, Cunningham BL. Saline-filled Breast Implants: A Plastic Surgery Educational

Foundation Multicenter Outcomes Study. Plastic Reconstructive Surgery. 1997 (100): 1019-27.

11 Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton LJ. Complications leading to surgery

after breast implantatation. New Engl J Med 1997; 336:679-682.
24

4. Pain

Women may feel pain of varying severity (degrees) and duration (length of time)

following breast implant surgery. In addition, improper size, placement, surgical

technique, or capsular contracture may result in pain associated with nerve entrapment

or interference with muscle motion. You should tell your doctor if you have pain.

5. Dissatisfaction with Cosmetic Results

Dissatisfying results such as wrinkling, asymmetry, implant displacement (shifting),

incorrect size, unanticipated shape, implant palpability, scar deformity, hypertrophic

(irregular, raised scar) scarring, and/or sloshing may occur. Careful surgical planning

and technique can minimize but not always prevent such results.

Additionally, for saline-filled implants that have a valve, you also might be able to

feel the valve of the implant with your hand.

Repeated surgeries to improve the appearance of the breasts and/or to remove

ruptured or deflated prostheses may result in an unsatisfactory cosmetic outcome.

6. Infection

Infection can occur with any surgery. Most infections resulting from surgery appear

within a few days to weeks after the operation. However, infection is possible at any

time after surgery. Infections with an implant present are harder to treat than

infections in normal body tissues. If an infection does not respond to antibiotics, the

implant may have to be removed, and another implant may be placed after the

infection has cleared up.
25

In rare instances, Toxic Shock Syndrome has been noted in women after breast

implant surgery, and it is a life-threatening condition. Symptoms include sudden

fever, vomiting, diarrhea, fainting, dizziness, and/or sunburn-like rash. A doctor

should be seen immediately for diagnosis and treatment.

7. Hematoma/Seroma

Hematoma is a collection of blood inside a body cavity, and seroma is a collection of

the watery portion of the blood around the implant or around the incision.

Postoperative hematoma and seroma may contribute to infection and/or capsular

contracture. Swelling, pain, and bruising may result. If a hematoma occurs, it will

usually be soon after surgery; however, this can also occur at any time after injury to

the breast. While the body absorbs small hematomas and seromas, large ones will

require the placement of surgical drains for proper healing. A small scar can result

from surgical draining. Implant deflation/rupture can occur from surgical draining if

damage to the implant occurs during the draining procedure.

8. Changes in Nipple and Breast Sensation

Feeling in the nipple and breast can increase or decrease after implant surgery. The

range of changes varies from intense sensitivity to no feeling in the nipple or breast

following surgery. Changes in feeling can be temporary or permanent and may affect

sexual response or the ability to nurse a baby. (Refer to the Other Illnesses section for

more information on breast feeding.)

9. Calcium Deposits in the Tissue Around the Implant

Deposits of calcium can be seen on mammograms and can be mistaken for possible

cancer, resulting in additional surgery to biopsy and/or remove the implant to
26

distinguish these deposits from cancer. Calcium deposits may be felt as nodules (hard

knots) under the skin around the implant.

10.Delayed Wound Healing

In some cases, the incision site fails to heal normally or takes longer to heal.

11.Extrusion

An unstable or compromised tissue covering and/or interruption of wound healing

may result in extrusion of the implant, which is when the breast implant comes

through the skin. The additional surgery needed to correct this complication can

result in unacceptable scarring or loss of breast tissue.

12.Necrosis

Necrosis is the formation of dead tissue around the implant. This may prevent wound

healing and require surgical correction and/or implant removal. Permanent scar

and/or deformity may occur following necrosis. Factors associated with increased

necrosis include infection, use of steroids in the surgical pocket, smoking,

chemotherapy/radiation, and excessive heat or cold therapy.

13.Breast Tissue Atrophy/Chest Wall Deformity

The pressure of the breast implant may cause the breast tissue to thin and shrink. This

can occur while implants are still in place or following implant removal without

replacement.
27

14.Interference with Mammography

Interference with mammography due to breast implants may delay or hinder the early

detection of breast cancer either by hiding suspicious lesions (wounds or injuries or

tumors) or by making it more difficult to include them in the image. Implants

increase the difficulty of both taking and reading mammograms. Some women who

undergo reconstruction will have some breast tissue remaining, and some have all of

their breast tissue removed. It is important that a woman with breast tissue remaining

continue to have mammography of that breast, as well as of the other breast, to detect

breast cancer.

Mammography requires breast compression (hard pressure) that could contribute to

implant rupture. In addition to special care taken by the technologist to reduce the

risk of implant rupture during this compression, other techniques are used to

maximize what is seen of the breast tissue during mammography. These techniques

are called breast implant displacement views, Eklund displacement views, or Eklund

views, after the radiologist who developed them. These special implant displacement

views are done in addition to those views done during routine mammograms.

Because of the extra views and time needed, women with implants should always

inform the receptionist or scheduler that they have breast implants when making an

appointment for mammography. They should also tell the radiology technologist

about the presence of implants before mammography is performed. This is to make

sure that the technologist uses these special displacement techniques and takes extra

care when compressing the breasts to avoid rupturing the implant.

The displacement procedure involves pushing the implant back and gently pulling the

breast tissue into view. Several factors affect the success of this special technique in

imaging the breast tissue in women with breast implants. The location of the implant,
28

the hardness of the capsular contracture, the size of the breast tissue compared to the

implant, and other factors may affect how well the breast tissue can be imaged.

Also, a radiologist may find it difficult to distinguish calcium deposits in the scar

tissue around the implant from a breast tumor when he or she is interpreting the

mammogram. Occasionally, it is necessary to remove and examine a small amount of

tissue (biopsy) to see whether or not it is cancerous. This can frequently be done

without removing the implant.

15.Galactorrhea

Sometimes after breast implant surgery, you may begin producing breast milk. In

some cases, the milk production stops spontaneously or when medication is given to

suppress milk production. In other cases, removal of the implant(s) may be needed.
29

OTHER ILLNESSES

Some women with breast implants have reported health problems that they believe are

related to their implants, but most studies of these illnesses have failed to show an

association with breast implants. There also have been concerns about possible, but

unproven, effects on health.

Most of the health concerns about breast implants are related to silicone gel. Even if a

silicone gel-filled breast implant does not rupture, small amounts of the silicone fluid or

oil may bleed out of the implant and migrate into the surrounding tissue. There has been

concern that this escaped silicone fluid or oil might cause harmful effects, including

connective tissue disease and related disorders and/or cancer.

These other illnesses are discussed below.

1. Connective Tissue Diseases (CTDs) and Related Disorders

The body’s immune system is the network of cells that protect against infectious

diseases. Antibodies are one type of substance the body produces to fight off

infectious agents. CTDs and related disorders of the body's immune system are

related to the connective tissues of the body, which include fibrous tissues, cartilage,

and bone that support body structures and bind body parts together. Some CTDs are

autoimmune diseases that occur when a woman’s immune system attacks her own

cells as if they were foreign.

Defined autoimmune diseases include

• lupus

• rheumatoid arthritis

• polymyositis
30

• dermatomyositis

• progressive systemic sclerosis or scleroderma

Disorders that are not autoimmune include

• fibromyalgia

• chronic fatigue syndrome

Some women with breast implants have experienced the diseases and/or disorders

listed above, as well as a variety of signs and symptoms that could be related to the

immune system. However, this is not considered a defined disorder.

These signs and symptoms include

• pain and swelling of joints

• tightness

• redness or swelling of the skin

• swollen glands or lymph nodes

• unusual or unexplained fatigue

• swelling of the hands and feet

• excessive hair loss

• memory problems

• headaches

• muscle weakness or burning

Signs and symptoms such as these may be present in women without CTD or

related disorders or without breast implants. Individual cases alone cannot

scientifically prove or disprove a connection between CTDs and related disorders

and breast implants.
31

Some doctors and women have thought that these signs and symptoms are part of a

new disease which is related to silicone and have called the disease "human adjuvant

disease," "silicone related syndrome," "atypical disease," or other names. The IOM

report stated "The diagnosis of this condition could depend on the presence of a

number of symptoms that are nonspecific and common in the general population.

Thus, there does not appear to be even suggestive evidence of a novel [new]

syndrome in women with breast implants." So, it is unclear at this time whether the

signs and symptoms experienced by these women are related to their implants. In

some cases, women have reported fewer symptoms after the implants were removed.

In other cases, there was no change in signs and symptoms after the implants were

removed.

Studies have shown that some women with silicone gel-filled breast implants

produced antibodies to their own collagen (a connective tissue protein), but we do not

know how often these antibodies occur in the general population, and there are no

data that show these antibodies cause CTDs and related disorders.12,13,14 There are

reports of women with implants who have other autoantibodies. However, the

presence of these antibodies does not mean that a woman has an increased risk of

actually developing a CTD or related disorder.

Several other studies of women with breast implants have been completed recently.

These studies provide substantial, but not complete information, about the lack of a

possible association between breast implants and CTDs. For example:

 

12Wolf LE, Lappe M, Peterson RD, et al. Human immune response to polydimethylsiloxane (silicone): screening

studies in a breast implant population. FASEB J 1994;7:1265-1268.

13 Tueber SE, Rowley MJ, et al. Anti-collagen antibodies are found in women with silicone breast implants. J

Autoimmunity 1993;6:357-377.

14 Rowley MJ Cook AD, et al. Antibodies to collagen: comparative epitope mapping in women with silicone breast

implants, system lupus erythematosus and rheumatoid arthritis. J Autoimmunity 1994; 7:775-789.
32

• A study by Gabriel et al. of breast implants and CTDs, conducted at the Mayo

Clinic, compared the medical records of 749 women with breast implants in

Olmsted County, Minnesota, with a similar group of women from the same area

who did not have implants.15 The researchers concluded that there was no

increased risk of defined CTD and related disorders among the women with breast

implants.

• A study by Englert et al., conducted in Australia, found no increase in

scleroderma, a connective tissue disease whose possible connection to breast

implants had been the source of some concern.16

• A study by Sanchez-Guerrero, conducted at the Harvard Medical School, included

1183 women with silicone gel-filled, saline, double lumen, polyurethane coated

and 56 unknown breast implants.17 This study found no increase in CTDs.

• A 1996 study by Hennekens et al., also conducted at the Harvard Medical School,

is the largest study to look at the past experiences of women with breast

implants.18 Almost 400,000 women (nearly 11,000 with breast implants)

completed questionnaires for the study. The study showed a small but statistically

significant increase in the risk of all CTDs reported by women with breast

implants. The study indicated that over a 10-year-period, women with breast

implants were 1.24 times more likely to report having a CTD or related disorder

than women without breast implants. The increase in risk applies to all of the

CTDs and related disorders taken together. When calculated individually,

 

15 Gabriel SE, O'Fallon WM, Kurland LT, Beard CM, Woods JE, Mellon LJ. Risk of connective-tissue diseases and

other disorders after breast implantation. N Engl J Med 1994; 330:1697-1702.

16 Englert HJ, Brooks P. Scleroderma and augmentation mammoplasty--a casual relationship? Aust NZ J ME

1994;24:74-80.

17 Sanchez-Guerrero J, Colditz GA, Karlson EW, Hunder DJ, Speizer FE, Liang MH. Silicone breast implants and

the risk of connective-tissue diseases and symptoms. New Engl J Med 1995;322:1666-1670.
33

however, the risk for each of these diseases was not statistically significant.

According to this study, having breast implants did not increase the risk of getting

any one of these CTDs and related disorders when they are considered

individually.

When considered together, these studies indicate that the risk of developing a typical

or defined CTD or related disorder due to having a breast implant is low.

None of the studies described above can completely resolve the question of whether

silicone gel-filled breast implants increase the risk of CTDs and related disorders.

Without a group of women without implants who are of similar age, health, and social

status and followed for a long time (such as 10-20 years), a relationship between

implants and these diseases cannot conclusively be made. Also, except for the

Hennekens study, none of the studies has been large enough to rule out the possibility

that the implants could cause CTD or a related disorder in a small subset of women

who have them. Because these studies were largely designed to find out whether

women with the implants had certain well-defined CTDs and related disorders, they

also cannot exclude the possibility that some women with implants might develop

other signs and symptoms related to the immune system that are not a defined CTD.

In other words, these studies do not resolve the question of whether the variety of

signs and symptoms some women report might be related to their implants.

 

18 Hennekens CH, Lee I-M, Cook NR, Hebert PR, Karlson EW, LaMotte F, Manson JE, Buring JE. Self-reported

breast implants and connective-tissue diseases in female health professionals. JAMA 1996;275:616-621.
34

2. Cancer

The IOM report indicates that breast cancer is no more common in women with

implants than those without implants.19

At this time, there is no scientific evidence that silicone gel-filled breast implants can

increase the risk of other cancers in women, but this possibility cannot be completely

ruled out because the studies to evaluate the risk of other cancers have not been done.

About 10% of women with breast implants received the polyurethane foam-coated

type until they were taken off the market in 1991 because of concerns that the coating

might increase the risk of breast cancer. This coating released small quantities of the

chemical called TDA (2,4-toluenediamine) that has been shown to cause cancer in

animals. Because of this concern, the manufacturer of the coated implants, BristolMyers Squibb Company, analyzed the urine of women with these devices for TDA.20

Researchers found TDA in the urine but in such tiny amounts that the risk of cancer

from the polyurethane foam-coated implants is only about l in a million over a

woman's lifetime. Therefore, it is unlikely that even 1 of the estimated 110,000

women who got the polyurethane foam-covered implants will get cancer as a result of

exposure to the TDA. This study supports FDA's recommendation that women with

polyurethane foam-covered breast implants should not have them removed based

solely on concerns about cancer from TDA.

Concerns have also been raised about whether the TDA from the polyurethane-coated

implants could increase the risk of cancer to a nursing infant. FDA required the

 

19 Safety of Silicone Breast Implants. Institute of Medicine National Academy Press, Washington, D.C. 2000. {IOM

Report}

20 Hester TR Jr, Ford NF, Gale PJ, Hammett JL, Raymond RH, Turnbull D, Frankos VH, Cohen MB. Measurement

of 2,4,toluenediamine in the urine and serum samples from women with Meme or Replicon breast implants. Plast

Reconstr Surg, 1997;100:1291-1298.
35

manufacturer to analyze mother's milk for TDA, but the manufacturer was unable to

get enough lactating women with these implants to conduct a valid study.

3. Breast Feeding

Women of childbearing age who want to breast feed should be aware of the negative

impact of breast implants on breast feeding.

One concern is the ability to successfully breast feed after breast implantation. Some

women who undergo breast augmentation can successfully breast feed and some

cannot. Women who undergo a mastectomy will be unable to breast feed on the

affected side due to loss of breast tissue and glands that produce milk.

One study by Hurst reports that up to 64% of 42 women with implants were unable to

breast feed compared to 7% of 42 women without implants.21 This is the highest

reported range in the literature. While there have been no definitive studies regarding

this issue, having an implant may significantly affect your ability to breast feed.

It is not known if a small amount of silicone may pass from the silicone shell of an

implant into breast milk. If this occurs, it is not known what effect it may have on the

nursing infant. Although there are no current methods for detecting silicone levels in

breast milk, a study by Semple et al. measuring silicon (one component in silicone)

levels showed the same levels in breast milk from women with silicone gel–filled

implants when compared to breast milk from women without implants.22

 

21 Hurst NM. Lactation after augmentation mammoplasty. Obstet Gynecol 1996;87:30-34

22 Semple JL, Lugowski SJ, Baines CJ, Smith DC, McHugh A. Breast milk contamination and silicone implants:

preliminary results using silicone as a proxy measurement for silicone. Plast Reconstr Surg 1998;102:528-533.
36

4. Effects on Children

Concerns have been raised about the potential damaging effects on children born of

mothers with implants. The IOM report said that the information is insufficient or

flawed to draw definite conclusions about this issue 23. In other words, it is not known

what effect breast implants may have on a fetus and the nursing infant.

5. Other

There is some concern, but little information, about possible risks from the silicone

material of the shell from the saline-filled and silicone gel-filled breast implants.

Another concern relates specifically to saline-filled breast implants. Questions have

been raised about the potential for the saline to become contaminated (not sterile)

with fungus or bacteria and to be released into the woman's body if her implant

deflates or ruptures or if the valve leaks. However, saline-filled implants are now

generally filled from a bag and tubing rather than from an open bowl, which should

reduce the risk of this complication. Also, the manufacturers have advised doctors

against adding any antibacterial, antiseptic, or cleansing agent to the saline as it may

decrease the strength of the implant shell.

 

23 Safety of Silicone Breast Implants. Institute of Medicine National Academy Press, Washington, D.C. 2000. {IOM

Report}
37

SPECIFIC ISSUES TO CONSIDER

In the Introduction section, factors for you to consider when deciding whether or not to

have breast implants were provided. Additionally, the previous sections describe the

risks and other illnesses of breast implants. The following are additional issues for you to

consider in your decision making process, including questions to ask your surgeon.

OTHER FACTORS TO CONSIDER IN BREAST IMPLANTATION

1. Choosing a Surgeon -

When choosing a surgeon who is experienced with breast implantation, you should

know the answers to the following questions:

a. How many breast augmentation or reconstruction implantation procedures does

he/she perform per year?

b. How many years has he/she performed breast implantation procedures?

c. Is he/she board certified, and if so, with which board?

d. In which states is he/she licensed to practice surgery? Note that some states

provide information on disciplinary action and malpractice claims/settlements to

prospective patients either by request or on the World Wide Web.

e. What is the most common complication he/she encounters with breast

implantation?

f. What is his/her reoperation rate with breast implantation and what is the most

common type of reoperation he/she performs?

When you have answers to these questions, you will have a better idea of the technical

qualifications of your surgeon.
38

2. Implant Shape and Size

Depending on the desired shape you wish to achieve, you and your surgeon may

choose a round or contoured implant shape. Generally, the larger you want your cup

size, the larger the breast implant the surgeon will consider (measured in cubic

centimeters, or cc’s). You should be aware that contoured implants that are placed

submuscularly (under the pectoralis major muscle) may assume a round shape after

implantation.

Your surgeon will also evaluate your existing tissue to determine if you have enough

to cover the breast implant. If you desire an implant size too large for your tissue,

your surgeon may warn you that breast implant edges may be apparent or visible postoperatively. You may even risk surgical complications. Also, excessively large

breast implants may speed up the effects of gravity and result in earlier droop or sag.

3. Surface Texturing

Textured surface implants were designed to reduce the chance of capsular contracture.

Some studies with small numbers of women suggest that surface texturing reduces the

chance of severe capsular contracture, but studies of a large number of women with

saline-filled implants show no difference in the likelihood of developing capsular

contracture with textured implants compared to smooth surfaced implants.

4. Palpability

The following may cause implants to be more palpable (more easily felt)

• textured implants

• larger implants

• subglandular placement (on top of the muscle and under the breast glands)
39

• smaller amount of skin/tissue available to cover the implant

5. Implant Placement

The breast implant can be placed either submuscularly or subglandularly. You should

discuss with your surgeon the pros and cons of the implant placement selected for

you.

Submuscular Placement

Possible Results

Subglandular Placement

Possible Results

Surgery may be longer Surgery may be shorter

Recovery may be longer Recovery may be shorter

Reoperation may be more difficult May provide easier access for reoperation

Less palpable implants More palpable implants

Easier imaging in mammography More difficult imaging in mammography

The sketches below show the differences between subglandular and submuscular

placement of your implant compared to a breast before augmentation.

 

Breast before augmentation Breast after Breast after

subglandular augmentation submuscular augmentation
40

6. Incision Sites

Augmentation Incision Sites – The three common incision sites are under the arm

(axillary), around the nipple (periareolar), or within the breast fold (inframammary).

If the incision is made under the arm, the surgeon may use a probe fitted with a

miniature camera, along with minimally invasive (very small) instruments, to create a

"pocket" for the breast implant.

• Periareolar – This incision is most concealed but is associated with a higher

likelihood of inability to successfully breast feed, as compared to the other

incision sites.

• Inframammary – This incision is less concealed than periareolar but associated

with less difficulty with breast feeding than the periareolar incision site.

• Axillary – This incision is less concealed than periareolar but associated with less

difficulty than the periareolar incision site when breast feeding.

• Umbilical/endoscopic – This incision site is not recommended.

 

Under arm

(transaxillary)

incision

In breast fold

(inframammary) incision

Around nipple

(periareolar)
41

Reconstruction Incision Sites - Most implants in breast reconstruction use the

mastectomy scar either immediately (during the mastectomy procedure) or after

tissue expansion.

You should discuss with your surgeon the pros and cons for the incision site

specifically recommended for you, depending on whether you will be having

augmentation or reconstruction.

As a note, the saline-filled implant is typically inserted empty and then filled with

saline to permit the smallest possible incision.
42

QUESTIONS TO ASK YOUR SURGEON ABOUT BREAST

AUGMENTATION

The following list of questions may help you to remind you of topics to discuss with your

doctor. You may have additional questions as well.

1. What are the risks and complications associated with having breast implants?

2. How many additional operations of my implanted breast(s) can I expect over

my lifetime?

3. How will my breasts look if I choose to have the implants removed without

replacement?

4. What shape, size, surface texturing, incision site, and placement site is

recommended for me?

5. How will my ability to breast feed be affected?

6. How can I expect my implanted breasts to look over time?

7. How can I expect my implanted breasts to look after pregnancy? After

breastfeeding?

8. What are my options if I am dissatisfied with the cosmetic outcome of my

implanted breasts?

9. What alternate procedures or products are available if I choose not to have

breast implants?

10. Do you have before and after photos I can look at for each procedure and what

results are reasonable for me?
43

QUESTIONS TO ASK YOUR SURGEON ABOUT BREAST

RECONSTRUCTION

The following list of questions may help to remind you of topics to discuss with your

doctor. You may have additional questions as well.

1. What are all my options for breast reconstruction?

2. What are the risks and complications of each type of breast reconstruction

surgery and how common are they?

3. What if my cancer recurs or occurs in the other breast?

4. Will reconstruction interfere with my cancer treatment?

5. How many steps are there in each procedure, and what are they?

6. How long will it take to complete my reconstruction?

7. How much experience do you have with each procedure?

8. Do you have before and after photos I can look at for each procedure and what

results are reasonable for me?

9. What will my scars look like?

10. What kind of changes in my implanted breast can I expect over time?

11. What kind of changes in my implanted breast can I expect with pregnancy?

12. What are my options if I am dissatisfied with the cosmetic outcome of my

implanted breast?

13. Would you suggest other patients I could talk to about their experiences?

14. What is the estimated total cost of each procedure?

15. How much pain or discomfort will I feel, and for how long?

16. How long will I be in the hospital?

17. Will I need blood transfusions, and can I donate my own blood?

18. When will I be able to resume my normal activity (or sexual activity, or

athletic activity)?
44

FREQUENTLY ASKED QUESTIONS

What information should I get for my records?

If you are going to receive a breast implant, there are several important items of

information you should have for your personal records before your surgery.

• Patient information: This may be in the form of a brochure, an information sheet,

or an informed consent document.

For the approved saline-filled breast implants made by Mentor and McGhan, there

are patient informed decision brochures that are available through your doctor,

Mentor or McGhan, or on FDA’s website at

http://www.fda.gov/cdrh/breastimplants. These brochures describe the approved

uses for those implants, factors to consider in your decision, risks, clinical results,

etc. The brochures are to assist you in making your decision about whether or not

to have these saline-filled breast implants.

To date, for all other breast implants other than Mentor’s or McGhan’s saline-filled

implants (whether saline-filled or silicone gel-filled), you must be enrolled in a

FDA-approved clinical study called an IDE study to receive the implant in the U.S.

Additionally, you must sign the IDE informed consent document before surgery.

The informed consent document for an IDE study describes the purpose of the

clinical study, the risks associated with breast implants, etc. It is advisable that

you obtain a copy of the informed consent document from your doctor well in

advance of your surgery so that you may better understand the risks involved

and ask questions. This should be kept as part of your records.
45

Note that the informed consent document described above is required for you to

participate in an IDE study. This should not be confused with a standard consent

form that a hospital requires to be signed by any patient.

Aside from the informed consent document required to participate in an IDE

study, the patient labeling for the Mentor and McGhan saline-filled breast

implants and this consumer handbook provide additional information for you

to consider in your decision about whether or not to have breast implants.

• Package insert: You should also ask for a copy of the manufacturer's package

insert for the breast implant you will receive. Each package insert contains

important information about the precautions to be taken and the risks associated

with the specific brand of implant. You should use this insert as a basis for

discussion about the surgery with your doctor, and keep it for future reference.

• Manufacturer's device sticker: A copy of the sticker identifies the brand of the

implant you will receive, its size, and the manufacturer's lot number. This data

should be part of your personal medical record. It will be useful if you should have

problems following surgery or seek care from another health care provider.

Therefore, you should seek this information as soon as possible because doctors and

hospitals do not keep medical records forever.

• Insurance coverage: Breast implant surgery (whether breast reconstruction or

augmentation) and/or treatment of complications may not be covered by your health

insurance. You should check with your insurance company regarding these

coverage issues because, for some women, health insurance premiums may

increase, coverage may be dropped, and/or future coverage may be denied. Before

surgery, be sure to get, in writing, answers from your insurance company to these

questions, at minimum:
46

⇒ Does my policy cover the costs of the implant surgery, the implant, the

anesthesia, and other related hospital costs? To what extent?

⇒ Does it cover removal and/or replacement of the implants if this becomes

necessary? To what extent?

⇒ Does it cover the cost of detecting or treating a complication as a result of

either the implant or the reconstruction? To what extent?

⇒ Will there be an increase in my insurance premium? To what extent?

⇒ Will future coverage be affected? To what extent?

Note that policies on coverage may change from year to year due to numerous

reasons.

Should I tell other doctors in the future about my implants?

Yes. Whenever you give a medical history, be sure to inform the doctor that you have

breast implants, just as you would tell him or her about other previous surgical

procedures.

Do I need to get regular mammograms?

Women with breast implants who are in an age group where routine mammograms are

recommended should be sure to have these examinations at the recommended regularly

scheduled times. (Those who have had breast cancer surgery on both breasts should ask

their doctors whether mammograms are still necessary.) However, women should be

aware that breast implants may interfere with the detection of cancer and that
47

mammograms do not detect implant ruptures or leakage. The Breast Implant Risks

section discusses rupture/leakage and the method of detection of rupture/leakage.

What about the Trilucentä (soybean oil-filled) implants?

The Trilucent is a breast implant with a silicone shell filled with purified soybean oil.

LipoMatrix Inc., a subsidiary of Collagen Aesthetics, Inc. (DBA Collagen Corporation)

was the former owner of this IDE. Now AEI Inc. (a company owned by Inamed) is the

owner of this IDE. About 470 women (about 200 of who are in the U.S.) were enrolled

in an IDE study to evaluate the safety and effectiveness of the implant. In 1997, the

manufacturer stopped enrolling new patients into the IDE study. The IDE patients are

being evaluated, and no new clinical studies are planned for this breast implant.

While these implants were never approved for marketing in the U.S., they were approved

for marketing in Europe. The Medical Device Agency (MDA), the British equivalent of

the FDA, removed the Trilucent implant from the market in the United Kingdom in

March 1999 as a result of their investigation of reported adverse events. Their concern

was that breakdown products of the soybean oil filler in Trilucent implants removed

from some women were significantly different than the breakdown products predicted

during preclinical testing. These breakdown products could result in some substances

that are biologically active (react with body tissues), the toxic effects of which have not

been adequately evaluated, but which could be cancer-causing. The MDA recommended

that a woman with the Trilucent breast implant should consult her general practitioner

or the doctor who performed the initial implantation. The MDA also advised that a

woman should seek her doctor immediately if she notices unusual breast swelling or

inflammation associated with a Trilucent breast implant.
48

After more research, in June 2000, the MDA issued a Hazard Notice entitled,

“Trilucent Breast Implants: Recommendation to Remove” and a statement entitled,

“Statement on the Safety of Trilucent Breast Implants.” Both are available on MDA’s

website at http://www.medical-devices.gov.uk. Based on new toxicology information

provided by AEI Inc. and reviewed by the Independent Advisory Group set up by MDA,

the MDA recommended several immediate actions for women implanted with the

Trilucent breast implants in the U.K. Among these actions, women were advised to

have their Trilucent breast implants removed and to avoid pregnancy and breastfeeding while they still are implanted with their Trilucent implants. FDA worked with

McGhan Medical (a company owned by Inamed and responsible for the U.S. clinical

study) to develop a plan to contact all patients in the U.S. IDE study and request that they

come in for an evaluation and for a discussion of the MDA findings and

recommendations. Additional information from McGhan is available at

http://www.mcghan.com/trilucent/mcghan%20release.html and

http://www.trilucentinfo.com/. If you have questions regarding the Trilucent implant,

you should contact McGhan (refer to Breast Implant Resource Group section).

Is there a test to detect silicone in the body or to determine if an individual is

sensitive to silicone?

Currently, there are no FDA-approved tests to detect silicone in the body or to determine

whether a woman's immune system is sensitive to any component of silicone breast

implants.

Determining that silicon or silicone is present in body fluids does not indicate whether a

person is sensitive to these substances or at risk for any specific disease. (Silicon is an

element that is one component of the polymer silicone and is one of the most abundant

elements on the earth. Everyone is exposed to silicon.) Some researchers reportedly
49

have developed a test that can detect antibodies to silicone in blood; however, the proven

accuracy and usefulness of the test has not been determined. Some researchers have also

reported that a test called the Anti-Polymer Antibody Assay may be able to distinguish

signs and symptoms of disease ranging from mild to severe in women with implants.

However, the biologic basis for the assay has not been established. The test remains to be

proven as accurate, and, at this time, the clinical usefulness of the test results has not been

determined.

Even if such antibodies were detected, the importance would be unclear. Antibodies to

silicone would not necessarily mean that silicone is harmful or that a person would

necessarily have an adverse reaction to it. Some researchers have also reportedly

developed a test to detect if a woman's immune system is sensitive to silica, a component

found in silicone breast implants. The accuracy of this test also has been questioned, and

it is not clear at this time whether the results of this test have clinical usefulness.

Even if simple techniques to detect silicone were available, they might not be useful in

detecting a rupture because small amounts of silicone oil ordinarily bleed even from

intact implants. Further, because silicone is found in food and many other products,

including commonly used medicines and cosmetics, the tests would not easily determine

whether the silicone came from the implant or another source.
50

REPORTING OF SERIOUS PROBLEMS /MEDWATCH

What is MedWatch?

MedWatch, the FDA Medical Products Reporting Program, is designed to

• educate all health professionals about the critical importance of being aware of,

monitoring for, and reporting adverse events and problems to FDA and/or the

manufacturer

• ensure that new safety information is rapidly communicated to the medical

community thereby improving patient care

These MedWatch databases consist of information from adverse event and product

problem reports that FDA receives from manufacturers, user facilities, distributors,

importers, and the general public.

These databases of adverse reports are most useful as an early warning system when the

hazards of a device are previously unknown. FDA also uses these databases to follow

trends with particular devices and look for signals that further follow-up could be needed.

What is an adverse event?

An adverse event is any undesirable experience associated with the use of a medical

product in a patient. The event is serious and should be reported when the patient

outcome is:
51

• Death: Report if the patient’s death is suspected as being a direct outcome of the

adverse event.

• Life-threatening injury or illness: Report if the patient was at substantial risk of

dying at the time of the adverse event or it is suspected that the use or continued use

of the product would result in the patient’s death.

• Hospitalization: Report if admission to the hospital or a longer hospital stay

results because of the adverse event.

• Disability: Report if the adverse event resulted in a significant, persistent, or

permanent change, impairment, damage or disruption in the patient’s body function

or structure, physical activities, or quality of life.

• Birth Abnormality: Report if there are suspicions that exposure to a medical

product prior to conception or during pregnancy resulted in an adverse outcome in

the child.

· Medical or surgical intervention: Report if you suspect that the use of a medical

product resulted in a condition that required medical or surgical intervention to

prevent permanent impairment or damage to a patient.

What is a product problem?

Product problems (a defective or malfunctioning device problem) should be reported

when there is a concern about the quality, performance, or safety of any medication or

device. Problems with product quality may occur during manufacturing, shipping, or

storage.
52

They include

• product contamination

• defective parts

• poor packaging or product mix-up

• questionable stability

• device malfunctions

• labeling concerns

With drugs, the pharmacist is often the first to recognize a product quality problem.

Nurses are often the first to recognize a problem with a medical device. These suspicions

should be reported to FDA through MedWatch.

How many reports of adverse events or product problems has FDA received?

From 1985 until January 2000, FDA received 127,770 adverse reaction reports for

silicone gel-filled breast implants. During the same time period, FDA received 65,720

adverse reaction reports for saline-filled implants. (There may be some duplicate

reports.) The greater number of reports for silicone gel-filled implants does not

necessarily mean that there are more problems with this type of implant but may reflect

that more women received silicone gel-filled implants than saline-filled implants. There

were 1712 additional summary reported problems in which the type of implant was

unknown.

As of January 2000, FDA received 123 reports of deaths reportedly related to breast

implants. The reports are not confirmed by autopsy, and they do not show that breast

implants necessarily caused the deaths. In fact, in some cases, the actual cause of death

was not specified. A few of the reports related the cause of death to the surgical

procedure for implants. This included problems with anesthesia during surgery, deaths
53

from surgical complications such as hemorrhage (heavy blood loss), or infection. The

reports did not show that the implants themselves caused the reported deaths.

There were a few reports of women dying of the complications of diseases such as cancer

or CTDs (e.g., rheumatoid arthritis). However, because these illnesses occur in people

with and without the implants, there is no evidence that the implant actually caused the

illnesses or the deaths. According to the scientific studies done so far, women do not

have a significantly greater risk of illness, including scleroderma, rheumatoid arthritis

and cancer, or death if they have breast implants (refer to the Other Illnesses section).

How are serious adverse events and device problems reported to the FDA?

Serious adverse events and product problems should be reported to the FDA either

directly or through the manufacturer of the product.

User facilities (such as hospitals, nursing homes, etc.), under the Safe Medical Device

Act of 1990 (SMDA), are legally required to report suspected medical device-related

deaths to both FDA and the manufacturer, if known, and serious injuries to the

manufacturer or to FDA if the manufacturer is unknown. Health professionals within a

user facility should become familiar with their institution's procedures for SMDA

reporting. Within a user facility, reporting deaths and serious injuries that occur with the

use of medical devices is required by federal law and regulation. Meanwhile, reporting

adverse events and product problems with medications (drugs and biologics) and special

nutritions, although considered vital, is strictly voluntary.

Consumers and healthcare professionals should use the MedWatch program for reporting

significant adverse events with medical products.
54

If you believe that you have experienced one or more serious problems related to your

breast implants, we encourage you to have your healthcare professional report the

problem(s) to the FDA. Although reporting by physicians or other health professionals is

preferred, you may also report any serious problem directly through the MedWatch

voluntary reporting system. If you are participating in a study, you should be reporting

problems to your doctor so that information will be included in the study. However, if

you wish, you may also report a serious problem directly to MedWatch. You should

identify the study that you are participating in so that your problem report can be

included in the appropriate database.

If you are a healthcare professional, call 1-800-332-1088 to receive a form or to report by

phone.

If you are a consumer, call 1-888-463-INFOFDA (1-888-463-6332), from 10:00am –

4:00pm Eastern Time, Monday through Friday, to receive an FDA MedWatch Package.

Ask your doctor to complete the MedWatch form and keep a copy of the completed form

for your records.

For you to report a serious adverse event or device problem directly to FDA, use

MedWatch form 3500. This form may be obtained through FDA’s website at

http://www.fda.gov/medwatch/index.html. Instructions for completing this form are

located at http://www.fda.gov/medwatch/report/consumer/instruct.htm.

Mail the completed form to MedWatch, FDA Medical Products Reporting Program, Food

and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20852-9787, or fax it

to 1-800-332-1088.
55

The following information should be included in a MedWatch report

• the event or problem, described in detail

• the manufacturer, model, and brand name of the implant

• whether it is silicone gel or saline filled

• the year implanted and (if this applies) the year removed

• implant position/placement and size

• the reason implanted and the reason for removal (if this applies)

• diagnosis by your doctor (please include only information confirmed by a

doctor's diagnosis)

• names of implanting and diagnosing doctors

• whether silicone has migrated, and if so, where and how this has been

confirmed

• number of surgeries

You may attach records or other supporting material to the completed MedWatch form if

you think it will be helpful to FDA.

Every voluntary report is read individually and reviewed by a health professional at FDA,

who sends the reporter an acknowledgment letter. FDA will not contact you again unless

we need additional information. The report is analyzed, coded, and used to assist FDA in

taking regulatory actions. FDA will follow-up on unusual adverse events. The data are

evaluated for trends every few months and used as background information for studies of

adverse events with breast implants.
56

CHRONOLOGY OF FDA BREAST IMPLANT ACTIVITIES

• May 28, 1976: The Medical Device Amendments were enacted, giving FDA

authority to regulate medical devices such as breast implants, which were already

on the market.

• July 23, 1976: The FDA General and Plastic Surgery Devices Panel (referred to as

the Panel) recommended that breast implants be placed in class II, requiring general

controls and performance standards. As a note, under the law, there are three

regulatory categories for medical devices. Class I devices are usually simple

devices whose risks can be controlled by labeling and the manufacturing process.

Class II devices require additional measures, called special controls, to control risks.

Special controls may include performance standards, postmarket surveillance

studies, user education, or other measures. If there is a lack of information about

whether a device is safe and effective, it is put into class III, and the highest level of

premarket review is required. Class III devices include innovative (creative),

medical breakthrough, and new technology devices, as well as devices with poorly

established or questionable safety and effectiveness.

• January 19, 1982: Because of some reports of adverse events in the medical

literature, FDA announced a proposal to place breast implants in class III. Class III

devices have strict controls for safety and effectiveness.

• June 24, 1988: FDA classified all breast implants into class III. After a prescribed

waiting period of 30 months, FDA could require the submission of premarket

approval applications (PMAs) in which manufacturers present data showing the

safety and effectiveness of these devices.
57

• January - March 1989: An unpublished study showed that polyurethane foam,

which was used as a coating on certain types of silicone gel-filled breast implants,

would degrade and release 2-toluene diamine (TDA), a chemical known to cause

cancer in animals, under conditions of high temperature and alkalinity. FDA

requested specific information from the manufacturer about the chemical make up

and safety testing of polyurethane foam. Shortly afterwards, the manufacturer of

polyurethane-coated breast implants removed them from the market.

• May 17, 1990: FDA issued a proposed 515(b) regulation (call for safety and

effectiveness data) in the Federal Register on silicone gel-filled implants.

• February 1-2, 1991: FDA sponsored a Conference on Silicone in Medical Devices.

This was an exchange of scientific information and views on the applications of

silicone in medical devices.

• April 10, 1991: FDA published a final 515(b) regulation in the Federal Register that

required manufacturers of silicone gel-filled implants to submit PMAs with data

showing the safety and effectiveness of the implants by July 9, 1991.

• June 1991: FDA required the manufacturer of polyurethane-coated implants to

conduct research on the material. In taking this action, FDA made the first use of

new postmarket surveillance authority under the Safe Medical Devices Act of 1990.

• July 31, 1991: The Panel reviewed FDA's risk assessment of polyurethane foam

coating. The Panel found that the risk of cancer, if any, appears small and would

very likely be outweighed by the surgical risk involved in removing a polyurethanecoated implant.
58

• August 22, 1991: FDA determined that PMAs submitted by three manufacturers of

silicone gel-filled implants did not contain sufficient data to warrant a full review.

• September 26, 1991: FDA issued a Notice in the Federal Register requiring

distribution of information to patients on the risks associated with saline-filled and

silicone gel-filled breast implants.

• November 12-14, 1991: FDA convened the Panel to consider whether the PMA

data received from the manufacturers was sufficient to establish that the silicone

gel-filled implants are safe and effective. Despite the lack of data, the Panel voted

unanimously (complete agreement) to advise FDA that the implants filled a public

health need for breast reconstruction and revision for medical or surgical reasons

and that the implants should continue to be available while the manufacturers

collected additional data.

• January 6, 1992: FDA called for a voluntary moratorium (delay) on the use of

silicone gel-filled implants until new safety information could be thoroughly

reviewed by the Panel.

• February 18, 1992: The Panel met again to review new information on silicone gelfilled implants. This included case reports of autoimmune diseases, information not

included in the manufacturers' original submissions to FDA, and evidence that some

early models may have leaked excessively.

• March 19, 1992: Dow Corning withdrew from the silicone implant market but

continued to supply gel to one implant manufacturer.

• April 16, 1992: FDA lifted the voluntary moratorium on breast implants. FDA also

announced its decision to allow silicone gel-filled implants on the market only
59

under controlled clinical studies for reconstruction after mastectomy, correction of

congenital deformities, or replacement of ruptured silicone gel-filled implants due

to medical or surgical reasons. Until the these clinical studies could be submitted

and reviewed, FDA authorized temporary limited distribution of silicone gel-filled

implants for reconstructive patients on an urgent need basis with a very detailed

informed consent form. FDA denied applications for using silicone gel-filled breast

implants for augmentation but planned that the manufacturers would later conduct

clinical trials that would include a limited number of augmentation patients (the

stage 3 or core studies).

• July 24, 1992: FDA approved Mentor Corporation’s stage 2 (or adjunct study

protocol) for silicone gel-filled implants for reconstruction and revision only.

• December 1992: Dow Corning announced that it would no longer make five

implant grades of silicone for sale after March 31, 1993, but that it would continue

to manufacture 45 other medical grades of silicone materials.

• January 8, 1993: FDA published a 515(b) proposal in the Federal Register calling

for safety and effectiveness data for saline-filled implants. The proposal provided

for a 60-day comment period.

• June 2, 1994: FDA sponsored a Part 15 Hearing on saline breast implants to hear

testimony from all interested parties concerning the timing of the agency's review of

the safety and effectiveness of saline-filled breast implants. FDA promised to make

a decision by the end of the year.

• July 15, 1994: FDA granted conditional approval of an IDE pilot study of 50

patients for a breast implant filled with a purified form of soybean oil (Trilucent

implant).
60

• October 21, 1994: FDA sponsored the workshop Alternatives to Silicone Breast

Implants. The workshop provided a forum for FDA to present draft guidance

concerning testing requirements for alternative breast implants.

• December 23, 1994: FDA issued a Talk Paper describing the types of studies

required to demonstrate the safety and effectiveness of saline breast implants and

the date the studies are expected to be completed. Preclinical data were submitted

throughout 1995. Final clinical data were expected by early 1999.

• April 20, 1995: FDA updated the patient information sheet (entitled “Information

for Women Considering Saline-Filled Breast Implants”) on the risks of saline-filled

breast implants that manufacturers give to physicians who, in turn, provide them to

patients considering implant surgery.

• January 11, 1996: FDA sent a letter to current and potential manufacturers of

silicone gel-filled breast implants detailing the type of information needed for core

studies (stage 3 studies) of the silicone gel-filled implants for augmentation,

reconstruction, and revision patients.

• September 4, 1996: FDA cleared Poly Implants Protheses (PIP) for marketing of

saline-filled breast implants through the 510(k) process.

• September 19, 1996: FDA received a Citizen's Petition from the Y-Me National

Breast Cancer Organization and other related organizations requesting that the FDA

ease restrictions on the availability of silicone gel-filled breast implants for women

who choose reconstruction after a mastectomy and who have other special medical

needs.
61

• February 11, 1997: FDA received a Citizen's Petition from implant recipients (who

reported significant problems with their silicone implants) requesting that the FDA

revoke permission granted to manufacturers to make silicone gel-filled breast

implants available to women with breast cancer and women who previously had

implants.

• May 20, 1997: FDA cleared Hutchinson International for marketing of saline-filled

breast implants through the 510(k) process.

• October 15, 1997: FDA sent letters in response to the two Citizen's Petitions dated

9/19/96 and 2/11/97. The FDA responded to both petitioners that we do not, at this

time, have sufficient information to change the current regulatory policy on silicone

gel implants.

• 1997: The Department of Health and Human Services (DHHS) asked the Institute

of Medicine (IOM) to conduct an independent, unbiased review of all past and

ongoing scientific research regarding the safety of silicone breast implants. A

committee of experts in relevant scientific and clinical areas was asked to evaluate

past and ongoing studies of the relationship, if any, between implants and systemic

disease; assess the biologic and immunologic effects of silicone and other chemical

components of breast implants; assess the impact of breast implants, if any, on the

offspring of women with implants; and assess the accuracy of mammograms.

• Spring 1998: The FDA completed a study to assess the rupture rate of silicone gelfilled breast implants.

• March 30, 1998: FDA approved McGhan Medical’s Stage 2 (or adjunct study)

protocol for silicone gel-filled breast implants for reconstruction and revision only.
62

• May 6, 1998: Mentor Corporation and its subsidiary, Mentor Texas, signed a

consent decree of permanent injunction, promising that the company would

manufacture its breast implants in compliance with the Quality System Regulation.

The Quality System Regulation is critical in helping to assure that medical devices

are consistently high in quality and are safe and effective. FDA permitted Mentor

to continue marketing its breast implants because the deficiencies in Mentor’s

manufacturing process were not shown to result in a significantly increased risk to

women who received this company’s breast implants.

• June 5, 1998: FDA approved McGhan Medical's IDE study for silicone gel-filled

breast implants for augmentation, reconstruction, and revision for a limited number

of patients at a limited number of sites.

• November 12, 1998: FDA received a Citizen's Petition from Hyman, Phelps &

McNamara requesting that FDA either withdraw the proposed rule calling for

PMAs or PDPs for the saline-filled breast implant or reopen the comment period to

allow interested persons to address the information that has become available since

the publication of the 1993 proposed call for PMAs or PDPs. This petition was

denied.

• February 1, 1999: FDA cleared Silimed, LLC for marketing of their pre-filled and

inflatable saline-filled breast implants through the 510(k) process.

• June 22, 1999: The IOM released a comprehensive review of the published

literature and ongoing studies on both saline-filled and silicone gel-filled breast

implants entitled “Safety of Silicone Breast Implants.” The IOM made a clear

distinction between local complications and systemic health concerns. The IOM

determined that there was insufficient evidence to establish that either or both types

of breast implants cause systemic health effects, such as autoimmune disease, and
63

that there were no new health or safety issues associated with the use of both types

of implants. The IOM also concluded that local complications are “the primary

safety issue with silicone breast implants.” These local complications include

rupture, pain, capsular contracture, disfigurement, and serious infection, which may

lead to medical interventions and repeat surgeries. For more information, refer to

http://books.nap.edu/catalog/9602.html for the IOM report, Safety of Silicone Breast

Implants, and to http://books.nap.edu/catalog/9618.html for the consumer booklet

on the IOM study, Information for Women about the Safety of Silicone Breast

Implants.

• June 30, 1999: FDA received a Citizen's Petition from Anne Stanswell requesting

that FDA ban the use of the silicone gel-filled breast implants. This petition was

denied.

• October 1999: FDA issued a draft guidance entitled, “Guidance on Preclinical and

Clinical Data and Labeling for Breast Prostheses.” This guidance is for saline,

silicone gel, and alternative breast implants and is intended to replace FDA’s other

guidances for individual types of breast implants.

• August 19, 1999: FDA published a final 515(b) regulation in the Federal Register

that required manufacturers of saline-filled implants to submit PMAs with data to

establish the relative safety and effectiveness of the implants within 90 days.

• March 1-3, 2000: Panel meeting was held to discuss the safety and effectiveness

data submitted in PMAs from Mentor, McGhan, and PIP. The Panel recommended

that Mentor and McGhan’s PMAs be approved with conditions and that the PIP

PMA be disapproved. Additionally, a day of this Panel meeting was dedicated

towards obtaining public input on patient labeling.
64

• May 10, 2000: FDA granted approval of Mentor’s and McGhan’s saline-filled

breast implant PMAs. The clinical trials conducted by Mentor and McGhan on

saline-filled breast implants provided data on the types and rates of local

complications experienced by patients. These complication data are provided in the

patient labeling available on our FDA website at

http://www.fda.gov/cdrh/breastimplants. The 3-year cumulative risk rates are also

summarized in our May 10, 2000 press release available at

http://www.fda.gov/bbs/topics/NEWS/NEW00727.html. Despite complications

experienced by some women, the majority of those women still in the McGhan and

Mentor studies after three years reported being satisfied with their implants;

however, this does not include women who had their implants removed due to

problems and were dropped from the studies. To date, all other saline-filled breast

implants are considered investigational.

• August 2, 2000: FDA approved Mentor’s IDE study for silicone gel-filled breast

implants for augmentation, reconstruction, and revision for a limited number of

patients at a limited number of sites.
65

BREAST IMPLANT RESOURCE GROUPS

The following list provides sources of information and organizations involved in breast implant

issues. The list is provided for information purposes only and does not constitute an

endorsement by the FDA of the information or recommendations they may provide. At the end

of this section is federal government contact information.

MANUFACTURERS

Current Manufacturers of Silicone Gel-Filled

Implants:

McGhan Medical Corp.

700 Ward Drive

Santa Barbara, CA 93111-2936

1-800-862-4426

Mentor Corp.

5425 Hollister Avenue

Santa Barbara, CA 93111

1-800-525-0245

Former Manufacturers of Silicone Gel-Filled

Implants:

Baxter Healthcare Corporation

1385 Centennial Drive

Deerfield, IL 60015

1-800-323-4533

Bioplasty, Inc.

1385 Centennial Drive

St. Paul, MN 55113

1-800-328-9105

Dow Corning Corporation

P.O. Box 994

Midland, MI 48686-0994

1-800-442-5442

Medical Engineering Corporation

(A Bristol-Myers Squibb Company)

2317 Eaton Lane

Racine, WI 53404

414-632-3717

Porex Technologies

500 Bohannon Road

Fairburn, GA 30213

1-800-241-0195

Surgitek (replaced by Medical Engineering Corp.)

3037 Mt. Pleasant Street

Racine, WI 53404

Current Manufacturers of Saline-Filled

Implants:

McGhan Medical Corp.

700 Ward Drive

Santa Barbara, CA 93111

1-800-862-4426

Mentor Corp.

5425 Hollister Avenue

Santa Barbara, CA 93111

1-800-525-0245

Poly Implants Protheses/USA

9831 East Evergreen St.

Miami, FL 33157

888-700-9831

Hutchison International, Inc.

7949 Jefferson Highway

Baton Rouge, LA

225-927-6800

Silimed, L.L.C.

802 Easy Street

Garland, TX 75042

888-423-7600

Novamed Medical Products Manufacturing, Inc.

623 Hoover Street N.E.

Minneapolis, MN 55369

612-378-1437

Former Manufacturer of Saline-Filled

Implants:

PMT Corporation

1500 Park Road

Chanhassen, MN 55317

1-800-626-5463
66

PHYSICIAN, NURSING, and INDUSTRY GROUPS

American Academy of Allergy & Immunology

611 East Wells Street

Milwaukee, WI 53202

414-272-6071

Fax: 276-3349

American Academy of Clinical Toxicology

Kansas State University

Comparative Toxicology Laboratories

Manhattan, KS 66506-5606

785-532-4334

Fax: 785-532-4481

Fred Oehme

American Academy of Cosmetic Surgery

401 N. Michigan Ave.

Chicago, IL 60611-4267

312-527-6713

Fax: 312-644-1815

Website: http://www.cosmeticsurgery.org

Email: aacs@spa.com

American Academy of Nurse Practitioners

P.O. Box 40130

Washington, D.C. 20016

202-966-6414

Fax: 202-966-2856

Dr. Jan Towers

American Association for Clinical Chemistry

2101 L Street, N.W.

Washington, D.C. 20037-1526

202-835-8744

Fax: 202-887-5093

Email: jrhame@aacc.org

American Association for Neurological Surgeons

22 South Washington Street, Suite 100

Park Ridge, IL 60068

708-692-9500

Fax: 708-692-2589

Email: bhr@aans.org

American College of Chest Physicians

3300 Dundee Road

Northbrook, IL 60062

847-498-1400

Fax: 847-498-5460

Email: chestp@aol.com

American College of Obstetricians & Gynecologists

409 12th Street, S.W.

Washington, D.C. 20024

202-863-2511

Fax: 202-488-3985

Email: kbryant@acog.com

America College of Osteopathic Ob/Gyn

900 Auburn Road

Pontiac, MI 48342

248-332-6360

Fax: 248-332-4607

Jaki Britton

American College of Radiology

1891 Preston White Drive

Reston, VA 22091

703-648-8904

Fax: 703-836-0567

American College of Surgeons

633 N. St. Claire Street

Chicago, IL 60611

312-202-5000

Fax: 312-202-5001

Website: http://www.facs.org

American Gastroenterological Association

6900 Grove Road

Thorofare, NJ 08086

609-848-9218

Fax: 609-853-5991

American Hospital Association (AHA)

Capitol Place, Building #3

50 F. Street N.W., Suite 1100

Washington, D.C. 20001

202-638-1100

Fax: 202-626-2345 (main receptionist desk)

Fax: 202-626-4630 (Fax directly to Dr. Bentley)

James D. Bentley, Ph.D., Senior Vice President for

Policy

American Medical Association

515 North State St.

Chicago, IL 60610

312-464-4370

Fax: 312-464-5896

Website: http://www.ama-assn.org

American Medical Women’s Association

801 N. Fairfax St.

Alexandria, VA 22314

703-838-0500

Fax: 703-549-3864

Eileen McGrath
67

American Nurses Association

Suite 100W

600 Maryland Ave., S.W.

Washington, D.C. 20024-2571

202-554-4444 x270

Fax: 202-651-7001

Website: http://www.nursingworld.org

American Physical Therapy Association

1111 North Fairfax Street

Alexandria, VA 22314

703-684-2782

Fax: 703-706-8519

American Public Health Association

1015 15th Street, N.W.

Washington, D.C. 20005

202-789-5600

Fax: 202-789-5661

American Society for Aesthetic Plastic Surgery

11081 Winners Circle, Suite 200

Los Alamitos, CA 90710

888-272-7711

Fax: 562-799-1098

Website: www.surgery.org

American Society for Microbiology

1325 Massachusetts Avenue, N.W.

Washington, D.C. 20005

202-737-3600

Fax: 202-737-0233

Email: amelnick@asmusa.org

American Society of Clinical Oncology

225 Reinekers Lane, Suite 650

Alexandria, VA 22314 USA

703-299-1058 or 888-282-2552

American Society of Plastic Surgeons

444 E. Algonquin Road

Arlington Heights, IL 60005

1-800-635-0635

Fax: 847-228-7099

Website: http://www.plasticsurgery.org

American Society of Plastic and Reconstructive

Surgical Nurses

East Holly Avenue, Box 56

Pitman, NJ 08071-0056

609-256-2340

Fax: 609-489-7463

Website: http://asprsn.inurse.com/

American Urological Association

1120 North Charles Street

Baltimore, MD 21201

410-727-1100

Fax: 410-223-4370

Email: aua@auanet.org

Association of Reproductive Health Professionals

2401 Pennsylvania Avenue, N.W., Suite 350

Washington, D.C. 20037

202-466-3825

Fax: 202-466-3826

Wayne Shields, President & CEO

Chemical Specialty Manufacturers Association

(CSMA)

1913 I Street, N.W.

Washington, D.C. 20006

202- 872-8110

Fax: 202-872-8114

Ralph Engel, President

College of American Pathologists

325 Waukegan Road

Northfield, IL 60093

708-446-8800

Fax: 708-446-8807

Emergency Care Research Institute (ECRI)

5200 Butler Pike

Plymouth Meeting, PA 19462

610-825-6000

Fax: 610-834-1275

Joel Nobel, President

Food and Drug Law Institute (FDLI)

1000 Vermont Avenue, N.W., Suite 200

Washington, D.C. 20005

202-371-1420

Fax: 202-371-0649

Email: comments@FDLI.org (comments)

Email: JSA@FDLI.org (announcements)

John C. Villforth, President

Health Industry Manufacturers Association (HIMA)

1200 G. Street, N.W., Suite 400

Washington, D.C. 20005

202-783-8700

Fax: 202-783-8750

Email: database@himanet.com

Alan H. Magazine, President

Health Resources Services Assoc./OWH

5600 Fishers Lane, Rm. 14-25

Rockville, MD 20857

301-443-8695

Fax: 301-443-8587
68

Medical Alley

1550 Utica Avenue, South

Minneapolis, MN 55416

612-542-3077

Fax: 612-542-3088

Thomas Meskan, Executive Director

Medical Device Manufacturers Association (MDMA)

1900 K Street, N.W. Ste. 300

Washington, D.C. 20006

202-496-7150

Fax: 202-496-7756

Email: snorthrup@medicaldevices.org

Stephen J. Northrup, Executive Director

National Black Nurses Association

8630 Fenton St. Suite 330

Silver Spring, MD 20910

301-589-3200

Fax: 301-589-3223

Millicent Gorham

National Medical Association

1012 10th St., N.W.

Washington, D.C. 20001

202-347-1895

Fax: 202-842-3293

Website: http://www.nmanet.org/

Yolanda Flemming
69

CONSUMER GROUPS

AMC Cancer Research Center

1600 Pierce St.

Denver, CO 80214

1-800-525-3777

American Cancer Society

1599 Clifton Rd. NE

Atlanta, GA 30329

1-800-ACS-2345

Website: http://www.cancer.org

Arthritis Foundation

PO Box 7669

Atlanta, GA 30357-0069

404-872-7100, x6350

1-800-283-7800

Website: http://www.arthritis.org

Boston Women's Health Book Collective

P.O. Box 192

West Somerville, MA 02144

617-625-0277

Fax: 617-625-0294

Breast Cancer Action

55 New Montgomery Suite 323

San Francisco, CA 94105

415-243-9301

Barbara Brenner

Cancer Hope Network

231 North Avenue West

Westfield, NJ 07090-1420

1-877-HOPENET

The Cancer Letter

P.O. Box 9905

Washington, D.C. 20016

202-362-1809

Fax: 202-362-1681

Kristen Goldberg

CANDO (Chemically Associated/Neurological

Disorders)

P.O. Box 682633

Houston, TX 77268-2633

281-444-0662

Fax: 281-444-5468

Email: keeling.m@worldnet.att.net

Center for Women Policy Studies

1211 Connecticut Avenue, Suite 312

Washington, D.C. 20036

202-872-1770

Fax: 202-296-8962

Leslie Wolfe

Central Texas Silicone Implant Support, Inc.

1900A Gracy Farms Lane

Austin, TX 78758

Phone & Fax: 512-837-5254

Email: jcraig@realtime.net

Children Afflicted by Toxic Substances (CATS)

413 Fort Salonga Road

Northport, NY 11768

631-757-4829

Fax: 631-757-4872

Email: catstoxic@aol.com

Coalition of Silicone Survivors (COSS)

P.O. Box 129

Broomfield, Co 80038-0129

970-506-9288

Fax: 970-506-9288

Email: coss1@uswest.net

Lynda Roth

Command Trust Network

256 South Linden Drive

Beverly Hills, CA 90212

Humantics Foundation for Women

Breast Implants: Recovery & Discovery

1380 Garnet #444

San Diego, CA 92109

858-270-0680

Email: Ilena@san.rr.com

and ilena2000@hotmail.com

Website: http://www.infoimplants.com/Quebec/Espoir/03.html and

http://www.toxic-exposure.com

Ilena Rose

Implant Information Foundation

P.O. Box 2907

Laguna Hills, CA 92653

International Cancer Alliance for Research and

Education

4853 Cordell Avenue, Suite 11

Bethesda, MD 20814

301-654-7933

Dave Hankins

Kentucky Women's Health Network

P.O. Box 5471

Louisville, KY 40255-0471

502-897-2774

Fax: 502-893-6200

Email: mtbears@worldnet.att.net
70

Lupus Foundation of America

1300 Piccard Drive, Suite 200

Rockville, MD 20850

1-800-558-0121

Fax: 301-670-9486

Email: lupusinfo@aol.com

National Alliance of Breast Cancer Organizations

9 East 37th St., 10th Floor

New York, NY 10016

212-889-0606

Fax: 212-939-1213

Email: Nabco.info@aol.com

Website: http://www.nabco.org/

Amy Langer

National Asian Women’s Health Org. (NAWHO)

250 Montgomery St., Suite 1500

San Francisco, CA 94104

415-989-9747

Fax: 415-989-9758

Jennifer Stoll-Hadayia

National Association for Women’s Health

300 N. Adams, Suite 328

Chicago, IL 60606-5101

312-786-1468

Fax: 312-786-0376

Email: fbloom@nawh.org

Felicia Bloom

National Black Women’s Health Project

600 Pennsylvania Ave., S.E. Suite 310

Washington, D.C. 20003

202-543-9311

Fax: 202-543-9743

Email: nbwhp@nbwhp.org

Website: http://www.nbwhp.org/

Julia Scott

National Breast Cancer Coalition

1707 L St., N.W. Suite 1060

Washington, D.C. 20036

202-296-7477

Jennifer Levin

National Breast Implant Task Force

P.O. Box 210503

West Palm Beach, FL 33414

561-791-2625

Fax: 561-791-4419

National Center for Policy Research for Women and

Families

1444 Eye Street, N.W., Suite 900

Washington, D.C. 20005

202-216-9507

Website: http://www.cpr4womenandfamilies.org/

Diana Zuckerman, Ph.D., Executive Director

National Chronic Fatigue Syndrome and Myalgia

Association

P.O. Box 18426

Kansas City, MO 64133

816-931-4777

National Council of Negro Women

633 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

202-737-0120

Fax: 202-737-0476

J. Lawrence Miller

National Women's Health Network

514 Tenth Street, N.W., Suite 400

Washington, D.C. 20004

202-347-1140

Fax: 202-347-1168

Website: http://www.womenshealthnetwork.org/

Cindy Pearson

National Women’s Health Resource Center

120 Albany St. Suite 820

New Brunswick, NJ 08901

202-537-4702

Fax: 301-320-3762

Beth Battaglino, Director of Marketing

Plaintiffs’ Liaison Council

2008 Second Avenue, N.

Birmington, AL 35203

205-252-6784

Fax: 205-252-0423

Email: dburchfield@breastimplant.org

Planned Parenthood

1120 Connecticut Avenue, N.W., Suite 461

Washington, D.C. 20036

202-785-3351

Fax: 202-296-2318

Jacquelyn Lendsey, VP Public Policy

Public Citizen Health Research Group

1600 20 St., N.W.

Washington, D.C. 20009

202-588-1000

Website: http://www.citizen.org/

Scleroderma Foundation

89 Newbury St

Danvers, MA 01923

1-800-722-HOPE

Fax: 978-750-9902

Email: sfinfo@scleroderma.org

Website: http://www.scleroderma.org/
71

The Silicone Survivors Support Network

P.O. Box 117

Fairhope, AL 36532

334-928-7731

The Society for Women’s Health Research

1828 L St., N.W. Suite 625

Washington, D.C. 20036

202-223-7009

Fax: 202-833-3472

Connie Tomber

Toxic Discovery Network, Inc.

1906 Grant Lane

Columbia, MO 65203

573-445-0861

Fax: 573-445-0861

Email: toxicdiscovery@plateauconsulting.com or

breastimplantinfo@plateauconsulting.com

Website:

http://www.plateauconsulting.com/toxicdiscoverynet

work/

Kathy Keithley Johnston, RN, Breast Implant

Consultant

Toxic 2 KIDS

915 Rustic Drive

Macon, MO. 63552

660-385-4621

Fax: 660-385-3289

On-line Newsgroup: toxic2kids@egroups.com

Website:

http://www.plateauconsulting.com/toxicdiscoverynet

work/toxickids.html

Chair: Cindy Fuchs-Morrissey –

Fuchs/Morrissey@hotmail.com

Co-Chair: Ed Brent – brentko@mindspring.com

United Silicone Survivors of the World, Houston

Chapter

12615 Misty Valley

Houston, TX 77066

281-448-9760 or 281-444-4796

Fax: 281-448-4330

Email: Keeling.m@worldnet.att.net

WASP-Wisconsin

Chetek, WI 54728

715-924-3691

The Women’s Research & Education Institute

(WREI)

1750 New York Ave., Suite 350

Washington, D.C. 20006

202-628-0444

Fax: 202-628-0458

Anne Stone

Y-ME National Breast Cancer Organization

212 West Van Buren

Chicago, IL 60607-3908

1-800-221-2141

Fax: 312-294-8597

Website: http://www.y-me.org/
72

FEDERAL GOVERNMENT

The Consumer Affairs Staff of FDA’s Office of Health and Industry Programs (OHIP) is

responsible for answering breast implant calls and distributing the breast implant

handbook.

To receive a copy of the breast implant handbook, please call 1-888-463-6332. When

prompted, press 1, press 3, press 1, press 6, and then press 2 for the handbook (or 1 to

hear the latest information on breast implants). The breast implant handbook may also be

obtained by visiting FDA’s website at

http://www.fda.gov/cdrh/breastimplants/indexbip.html.

The Consumer Affairs Staff at OHIP is available Monday through Friday, 8:00am to

4:30pm Eastern Time. To contact the Consumer Affairs Staff, use one of the following

options:

• Call 301-827-3990.

To speak to a Consumer Affairs Specialist during business hours, press 5. To

request information outside of business hours, press 4 and leave a message.

· Call 1-888-463-6332.

When prompted, press 1, press 3, press 2, press 4, and press 1. Then, to speak

to a Consumer Affairs Specialist during business hours, press 5, or to request

information outside of business hours, press 4 and leave a message.

• Fax 301-443-9535.

• Email DSMA@cdrh.fda.gov.

Additional information may be found by visiting another FDA website at

http://www.fda.gov/cdrh/consumer/index.shtml. Click on “Products Regulated” on the

left side, then click on “B” and scroll down to “Breast Implants.”
73

The following is additional federal government contact information:

Food and Drug Administration

Office of Consumer Affairs

5600 Fishers Lane, Rm. 16-59

Rockville, MD 20857

1-888-INFO-FDA

Food and Drug Administration

Office of Women's Health

5600 Fishers Lane, Rm. 14-62

Rockville, MD 20857

Food and Drug Administration

Center for Devices and Radiological Health

Office of Health and Industry Programs

HFZ-210

1350 Piccard Drive

Rockville, MD 20850

Food and Drug Administration

Center for Devices and Radiological Health

Division of Mammography Quality and Radiation

Programs

1350 Piccard Drive, HFZ-240

Rockville, MD 20850

Institute of Medicine

National Academy of Sciences

Committee on the Safety of Silicone Breast Implants

2101 Constitution Ave., N.W.

Washington, D.C. 20418

202-334-1318

Fax: 202-334-2939

Website: http://www2.nas.edu/hpdp/22f6/htm

National Cancer Institute

Office of Cancer Communications

Building 31, Room 10A-24

9000 Rockville Pike

Bethesda, MD 20892

1-800-4-CANCER (226237)

National Institute of Health/OWH

Office of Research on Women Health

Bldg. 1, Room 201

1 Center Drive

Bethesda, MD 20892

301-402-1770

Fax: 301-402-1798

Vivian Pinn

Medicare Hotline

1-800-MEDICARE
74

CURRENT BIBLIOGRAPHIES

The National Library of Medicine (NLM) offers publications in its Current

Bibliographies in Medicine (CBM) series free-of-charge through the World Wide Web.

Bibliographies in the CBM series are produced by staff of NLM's Reference Section in

collaboration with subject specialists from the National Institutes of Health and

elsewhere. Each bibliography is prepared by searching a variety of online databases and

covers a separate topic of current interest. The result is a subject-categorized list of

citations to the recent literature, primarily journal articles and books. CBMs may be

retrieved from the Library's Web site at http://www.nlm.nih.gov/pubs/resources.html.

The IOM report, Safety of Silicone Breast Implants, is available for sale from National

Academy Press, 2101 Constitution Avenue, N.W., Box 285, Washington, DC 20055 or

call 800-624-6242 or 202-334-3938 or through the web at

http://books.nap.edu/catalog/9602.html. The IOM report may also be read at the same

website for free. A consumer booklet on the IOM study, Information for Women about

the Safety of Silicone Breast Implants, can be purchased from the National Academy of

Sciences on their website at http://books.nap.edu/catalog/9618.html or read at the same

website for free.
75

FDA FREEDOM OF INFORMATION

We sincerely hope that the information in this packet has been of help to you. If you

need more information, please submit a written request to the FDA Freedom of

Information Staff.

The Freedom of Information Act (FOIA) allows anyone to request FDA records.

However, under FOIA, information that is deemed exempt from disclosure may not be

released to the public. Examples of this type of information typically include: preclinical

or clinical data from ongoing, completed or discontinued studies; mechanical drawings;

chemical compositions; etc. For instance, FDA cannot acknowledge the existence of an

investigational study unless we know that the manufacturer has gone public with that

information. Even then, in most cases, no details of that study can be given per FDA

regulations. We are not denying any request; however, this clarification is provided so

that you do not have unrealistic expectations on what information you can obtain through

FOIA.

To access additional information on FOIA, to check to see if the information you want is

already on FDA’s website, to find out about FDA public reading rooms, and to access the

complete handbook for requesting information through FOIA, please go to our website at

http://www.fda.gov/cdrh/foicdrh.html

If you want to request information under FOIA, you must submit a written request to the

following address:

Food and Drug Administration

Freedom of Information Staff (HFI-35)

5600 Fishers Lane 

Rockville, MD 20857

Fax: 301-443-1726

Voice Mail Message: 301-827-6500
76

The letter should include your name, address and telephone number, as well as a

statement of the desired records, identified as specifically as possible. A request for

specific information that is releasable to the public can be processed much more quickly

than a request for all information on a particular subject. There are fees for searching and

reviewing the information plus a charge of 10 cents per page. You are billed after your

request for information has been filled.

If you have submitted a FOIA request and you have questions relating to its status, please

write to:

Freedom of Information Staff (HFZ-82)

Center for Devices and Radiological Health

Food and Drug Administration

2094 Gaither Road

Rockville, MD 20850

Fax: 301-594-4792

Breast implant documents involving our recent PMA approvals for two saline-filled

breast implants may be of interest to you. For example, the Summary of Safety and

Effectiveness (SSE) for each PMA may be obtained through FOIA. However, the

transcripts for the March 1-3, 2000 Panel meeting for these saline-filled breast implants,

as well as the patient labeling, for these implants are already available on our website at

http://www.fda.gov/cdrh/breastimplants/.

Note: As an alternative source of information on breast implants, you should be aware

that there is a comprehensive collection of FDA breast implant documents handled by the

Plaintiffs’ Liaison Counsel, which is independent from FDA and its FOIA Staff. Upon

the order of Judge Pointer, FDA released all relevant breast implant information that we

had up to February 1993. If the information you are seeking occurred before this date,

you should consider contacting the Plaintiffs’ Liaison Counsel at the telephone number or

address below.
77

While FDA formerly referred to this comprehensive collection as the “Pointer

Compendium,” the Plaintiffs’ Liaison Counsel stated that you should refer to that

collection as “those documents produced by FDA to the national depository in the

national breast implant litigation MDL926.”

This comprehensive collection of documents, along with an objective index allowing a

requestor to access these documents, is available on CD. The collection includes items

such as

• material related to advisory panel meeting in 1991 and 1992

• Federal Register notice for silicone gel-filled implants

• correspondence and meeting minutes concerning silicone and breast implants

• public statements issued by FDA

• FDA meeting minutes discussing elements of informed consent for silicone

gel-filled implants

• documents related to compliance with FDA-imposed requirements

• documents in FDA field offices

• administrative files concerning breast implant manufacturers

• 10 PMA applications for silicone gel-filled breast implants as well as

correspondence and other related materials

• FDA filings in breast implant-related litigation

• testimony prepared for Congressional hearings regarding silicone gel implants

• material related to IND 2702 (Dow Corning’s early investigation into soft

tissue augmentation with silicone fluid injections)

The Plaintiffs’ Liaison Counsel may also be contacted for general assistance and information

on breast implant litigation.
78

Please be aware that there will be independent charges assessed for this information also.

Questions on the specific contents of this comprehensive collection or requests for

specific records are to be directed to:

Plaintiffs’ Liaison Counsel

2008 2nd Avenue

Birmingham, Alabama 35203

205-252-6784

Fax: 205-252-0423